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9ABSTRACT
Background: Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in the
Western countries. Typically, it is a slowly progressing disease, and treatment by cytostatics is
initiated after follow-up in a situation where the patient has an aggressive disease or develops
general symptoms. The major obstacle in treatment is drug resistance and, moreover, multidrug
resistance. Extensive research into the mechanisms or prognostic factors for chemo- or irradiation
resistance has produced few clinically encouraging results.
Aims: To  evaluate  (I) multidrug resistance in CLL and to define the impact of (I) previous
chemotherapy, (II)  surface  antigens,  (III) the mutation status of the immunoglobulin variable
region (IgHV) genes as well as (IV) programmed cell death, apoptosis, associated gene transcripts
in drug and irradiation resistance in CLL.
Material and methods: Peripheral blood samples from a cohort of 36 CLL patients were collected
and mononuclear cells, containing mainly CLL cells, were isolated. Nine drugs and two types of
irradiation were selected according to their usefulness in CLL therapy or on the basis of their
otherwise interesting mechanism of action. Doses causing 50 or 80% inhibition of living cells were
measured from prednisolon (ID50) and from all other drugs and irradiations (ID80), respectively.
In total, 2,376 duplicated cell cultures were performed to determinate these ID80 or ID50 values.
Expressions  of  34  surface  antigens  were  analysed  by  means  of  flow cytometry.  PCR assays  were
used to determine the mutation status of the IgHV genes. Apoptosis-associated gene mRNA
expressions (anti-apoptotic: Bcl2, Mcl1, Bcl2a1, Bcl2l1; and pro-apoptotic: Bax, Myc, Dapk1) were
analysed with QRT-PCR.
10
Results: Multidrug resistance was more common in the previously treated CLL group than the
untreated group, but concordances between drug therapy and in vitro drug resistance were poor.
Statistically significant correlation was confirmed between the sensitivities of the same-group drugs
chlorodeoxyadenosine and fludarabine. Correlation between two P-glycoprotein-dependent drugs,
vincristine and doxorubicin, was not demonstrated (I). There were no correlations between the
investigated surface antigens and drug or irradiation sensitivities. The nucleoside analogues’
(chlorodeoxyadenosine and fludarabine) responses could be divided in two groups by their CD80
expression; every patient expressing the CD80 surface antigen was sensitive to nucleoside
analogues,  whereas  all  resistant  cases  had  low  or  negative  CD80  expression  (II). IgHV mutation
status divided the CLL patients in two groups, unmutated (67%) and mutated (33%), but
statistically significant differences could not be confirmed in the drug or irradiation sensitivities
between these groups (III). A higher amount of cell-death-inductive pro-apoptotic gene transcripts
did not induce drug or irradiation sensitivity, and a higher amount of cell-death-preventive anti-
apoptotic gene transcripts did not induce drug or irradiation resistance (IV).
Conclusion: Chemotherapy induces drug and irradiation resistance. Drug resistance does not
always develop against the used chemotherapeutic agent, as chemotherapy may also expose to drug
resistance against some other agents. CD80 could be a surrogate chemosensitivity marker for
nucleoside analogues. The IgHV genes’ mutation status or apoptosis-associated genes are not
determinants of drug or irradiation resistance in vitro.
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TIIVISTELMÄ
Tausta: Krooninen lymfaattinen leukemia (KLL) on länsimaiden yleisin leukemia. Se on yleensä
hitaasti etenevä tauti, ja hoidot solunsalpaajilla aloitetaan vasta seurannan jälkeen, jos tauti muuttuu
nopeasti eteneväksi tai aiheuttaa yleisoireita. Lääkeresistenssi muodostuu yleensä hoidon
suurimmaksi ongelmaksi, ja usein ilmenee monilääkeresistenssiä. Lääke- ja säderesistenssiä on
tutkittu runsaasti, mutta kliinisesti merkittäviä tuloksia niin ennustetekijöistä kuin mekanismeista on
vähän.
Tavoite: Tutkia KLL-solujen (I) monilääkeresistenssiä ja arvioida (I) aiemman lääkehoidon, (II)
pinta-antigeenien, (III) immunoglobuliinien variaabelialueen (IgHV) geenimutaatioden ja (IV)
ohjelmoituun solukuolemaan, apoptoosiin, liittyvien geenien merkitystä lääkeresistenssin
ennustajina KLL:ssa.
Aineisto ja menetelmät: 36 KLL-potilaan verinäytteistä eristettiin mononukleaariset solut, joista
suurin osa edusti leukeemista kantaa. Yhdeksän lääkeainetta ja kaksi eri säteilylajia valittiin joko
sen vuoksi, että niitä käytetään KLL:n hoidossa kliinisessä työssä, tai niiden mielenkiintoisten
vaikutusmekanismien vuoksi. Lääkeaineista ja sädelajeista määritettiin annospitoisuus, jolla
saavutetaan 80 %:n vähenemä soluissa (ID80). ID80-arvot määritettiin 2376 rinnakkaisella
soluviljelmällä. 34 pinta-antigeenin pitoisuudet määritettiin virtaussytometrialla. IgHV-geenien
mutatoitumisaste määritettiin PCR:llä. Apoptoosiin liittyvien geenien (anti-apoptoottiset: Bcl2,
Mcl1, Bcl2a1, Bcl2l1 ja pro-apoptoottiset: Bax, Myc, Dapk1) mRNA-pitoisuudet määritettiin QRT-
PCR:llä.
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Tulokset: Monilääkeresistenssi oli yleisempää aiemmin hoidetuilta KLL-potilailta otettujen solujen
ryhmässä kuin hoitamattomassa ryhmässä. Hoidoissa käytettyjen lääkkeiden ja in vitro
-lääkeresistenssin välillä ei näyttänyt olevan merkittävää yhteyttä. Saman lääkeryhmän lääkkeiden,
klorodeoksyadenosiinin ja fludarabiinin, herkkyyksien välillä nähtiin selvä korrelaatio, mutta P-
glykoproteiiniriippuvien lääkkeiden, vinkristiinin ja doxorubisiinin, herkkyyksien välillä ei
näyttänyt olevan korrelaatiota (I). Lääke- ja säderesistenssin ja pinta-antigeenien välillä ei löytynyt
tilastollisesti merkittävää riippuvuutta. CD80-pinta-antigeeni jakoi nukleosidianalogiryhmän
lääkkeiden (klorodeoksyadenosiinin ja fludarabiinin) vasteet kahteen ryhmään: CD80:n
ilmeneminen KLL-soluissa herkisti solut näille lääkkeille, kun taas kaikilla resistenteillä potilailla
CD80:n ilmeneminen KLL-soluissa oli heikko tai negatiivinen (II). IgHV-mutatoitumisaste jakoi
potilasryhmän kahteen joukkoon: mutatoitumattomiin (67 %) ja mutatoituneisiin (33 %). Näiden
ryhmien välillä ei löytynyt tilastollisesti merkittävää eroa lääke- tai sädeherkkyyksissä (III).
Solukuolemaan johtavien pro-apoptoottisten geenien korkeampi ilmeneminen ei herkistänyt soluja
lääkkeille tai sädetykselle. Myöskään solukuolemalta suojaavien anti-apoptoottisten geenien
korkeampi ilmeneminen ei johtanut lääke- tai säderesistenssiin (IV).
Päätelmät: Lääkehoito altistaa lääke- ja säderesistenssille. Lääkeresistenssi ei aina kehity hoidossa
käytettyä lääkettä kohtaan, vaan lääkehoito voi altistaa lääkeresistenssin kehittymisen myös muita
lääkkeitä kohtaan. Nukleosidianalogien lääkevasteita voidaan ennustaa CD80:n ilmenemisen
perusteella. IgHV-mutatoitumisasteella ja apoptoosiin liittyvillä geeneillä ei näyttäisi olevan
yhteyttä lääke- tai säderesistenssiin.
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INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in the Western
countries. In Finland, roughly 200 new cases are diagnosed yearly (Finnish Cancer Registry 2010).
CLL mainly affects the older population – the average age of patients is 65 years at diagnosis. The
clinical course of CLL varies to a great extent: some develop an aggressive disease and die within
one year of diagnosis, while others survive longer than ten years (Chiorazzi et al. 2005). Therefore,
prognostic factors have a significant role in the diagnosis of CLL. The clinical staging systems by
Rai and Binet are powerful and easily achieved prognostic methods. The variation in the clinical
outcome with these staging systems is still quite extensive, and more exact prognostic factors are
needed. Different biological prognostic factors have been found, and the most remarkable of these
are chromosomal aberrations (17p deletion and 11q deletion), surface antigens of the leukaemic
cells (CD38), the expression of the zap70 protein and the mutation status of immunoglobulin
variable (IgHV) region genes (Van Bockstaele et al. 2009).
The development of chemo- or irradiation resistance is another important determinant
of patient outcome in CLL (Shanafelt 2009). The mechanisms of drug resistance have been
extensively investigated, and in vitro sensitivity studies have been shown to correlate with the
clinical outcome of chemotherapy (Bosanquet et al. 2009). However, the clinically encouraging
results have been few. The main known resistance mechanisms are based on i) diminished drug
concentration in the cell, ii) altered drug effect because of abnormal enzymatic activity, iii) altered
drug target enzymes or proteins, iv) enhanced DNA-repairing mechanisms or v) disturbances in
leading the cell to the programmed cell death (Kruh 2003).
The pathological basis of CLL is unknown, but dysregulation of programmed cell
death, apoptosis, seems to explain at least a part of the disease progression (Buggins and Pepper
2010). The current opinion on the accumulation of lymphocytes in CLL is that it is caused by i) a
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dysregulation of apoptosis and, specifically, an overexpression of the Bcl2 protein as well as ii) an
increased proliferation of lymphocytes (Messmer et al. 2005).
When chemotherapy for is initiated for a patient, the sensitivity to the
chemotherapeutic agent/agents of the leukaemic cells is not known. The current guideline for the
treatment of CLL is based on a combination of chemotherapeutic agents (Dighiero and Hamblin
2008). The clinical results can be optimised by individualising the chemotherapy (Bosanquet et al.
1999a). There are few clinically relevant prognostic factors for chemotherapy available – these are
chromosome 17p deletion and p53 protein mutation (Zenz et al. 2008a). These findings are quite
rare in CLL and cannot be considered an explanation for chemoresistance in most of cases.
The purpose of the present study series was to evaluate the prognostic impact of
apoptosis-associated genes, surface antigens and the mutation status of IgHV-region genes on the in
vitro sensitivities of leukaemic cells from 36 CLL patients to nine drugs and two types of
irradiation. Furthermore, the prevalence of cross-resistance and the impact of previous treatments
on drug resistance were evaluated.
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1 REVIEW OF THE LITERATURE
1.1. Chronic lymphocytic leukaemia
1.1.1. Definition and diagnosis
The term leukaemia comes from the Greek words “leukos” and “heima,” meaning white blood.
John Benett and Rudolph Virchow were the firsts to describe leukaemia as a blood disease in 1845,
and Virchow gave the condition its name, leukaemia (Hajdu 2003). In early 20th century, chronic
lymphocytic leukaemia (CLL) was described as one subgroup of leukaemia. It was described as a
disease where there should be an increase in lymphocytes in the blood and an enlargement of the
spleen and the lymph nodes (Pinkus 1905). Since then, the definition of CLL has become more
exact. The World Health Organisation classified the condition in 2008 as a mature B-cell neoplasm
composed of small monomorphic B lymphocytes in the peripheral blood, bone marrow, liver,
spleen and lymph nodes (Swerdlow et al. 2008). The diagnosis of CLL requires the presence of at
least 5x109 B-lymphocytes/ L in the peripheral blood, and the typical clonality of the malignant cell
should be confirmed by flow cytometry. The lymphocytosis should be present for at least 3 months,
and the degree of lymphocytosis in the bone marrow is characteristically over 30%. If the degree of
lymphocytosis is lower than 5x109 B lymphocytes/L and occurs in the absence of
lymphadenopathy, organomegaly or cytopenias, the condition should be considered a low-stage
CLL or monoclonal B lymphocytosis. Other lymphoproliferative diseases might be difficult to
distinguish from CLL, which is why flow cytometry and bone marrow examination should be
performed  (Hallek et al. 2008).
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1.1.2. Epidemiology
CLL is the most common type of leukaemia in Europe and North America, but it is rare in Asia. It
comprises roughly one third of all types of leukaemia (Altekruse 2010). In Finland slightly more
than 200 new cases are diagnosed every year (average in 2004–2008), 40% of them occurring in
women and 60% in men (Finnish Cancer Registry 2010). More than 90% of CLL patients are over
50 years old at diagnosis, and the highest incidence is between the sixth and seventh decades of life.
Women with CLL have a superior survival outcome when compared to men, and they experience a
better clinical outcome in terms of progression-free survival, even if the difference is not large
(Molica 2006).
Table 1. New CLL patients according to age groups in Finland in 2004–2008 (Finnish Cancer
Registry 2010).
AGE
GROUP
0–34 35–
39
40–
44
45–
49
50–
54
55–
59
60–
64
65–
69
70–
74
75–
79
80–
84
85>
MALE 1 1 5 24 34 58 81 86 99 96 66 62
FEMALE 1 3 7 19 14 41 46 39 45 63 60 88
1.1.3. Aetiology
The aetiology of CLL is poorly understood. Approximately 10% of individuals with CLL report a
family history of CLL and genetic factors thus seem to be at  least  a part  of the aetiology (Brown
2008). First-degree relatives of CLL patients have a 7–8.5-fold relative risk for developing CLL and
a 2.6-fold relative risk for having any form of lymphoproliferative malignancy (Goldin et al. 2009).
There are significant ethnicity-related differences in CLL incidence – the incidence of CLL in
Asians is significantly lower than Europeans or Americans. Migrant studies in CLL support the
hereditary component; low rates of CLL in Asians appear to remain stable with migration to the
Western countries (Pang et al. 2002).
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Some chemical exposures have been connected to excess incidence of CLL, and
people employed in agricultural occupations as well as the pesticides, rubber and petroleum
industries are over represented in CLL (Blair et al. 2007). There is no significant association
between ionizing radiation and CLL, even though ionizing radiation has been clearly connected to
other types of leukaemia (Schubauer-Berigan et al. 2007).
It has been postulated that infection agents could trigger CLL development. In recent
studies an increased occurrence of respiratory infections has been found before the CLL diagnosis
(Landgren et al. 2007; Anderson et al. 2009). The respiratory infections could also be a
consequence of the altered immunity preceding CLL. Moreover, similarities in the B-cell receptors
(BCR) of CLL patients support the idea of a common antigen trigger and support the hypothesis
that an antigen-driven process contributes to CLL pathogenesis (Messmer et al. 2004; Widhopf et
al. 2004).
1.1.4. Clinical features
The clinical course of CLL is subject to great variation: a third of the patients never need treatment,
for another third an initial indolent phase is followed by disease progression, and the remaining
third develop an aggressive disease and need to be treated from the beginning (Dighiero and
Hamblin 2008). In most of the cases, CLL diagnosis is made by coincidence – leukocytosis is
detected in a routine blood test, while the patient does not have any symptoms. Enlargement of the
neck, axillary or inguinal lymph nodes may also represent the first sign of CLL, but an enlargement
of the spleen or liver is rarely the first sign of disease. Fever, weight loss, night sweating and fatigue
are normally markers of progressive disease.
The majority of complications in CLL are related to the impaired immune function,
with most patients developing a reduction in immunoglobulin levels. Infections are the major
complication in CLL, and most of them are bacterial respiratory infections. Recurrent and chronic
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sinusitis,  bronchitis  and  pneumonia  are  common  in  CLL.  The  response  to  vaccinations  is  altered
due the altered immune function (Sinisalo et al. 2003). The risk of infection increases over time,
especially in treated patients with active disease, and infections are usually the cause of death in
advanced CLL (Dearden 2008).
Autoimmune complications are well-recognized in CLL, occurring in up to 25% of
patients at some time during the course of their disease (Hamblin 2006b). The most common
autoimmune complication is autoimmune haemolytic anaemia. Another possible autoimmune
complication is immune thrombocypenia. The increased risk of secondary malignancies seen in
CLL is likely to be related to the underlying immune impairment (Dearden 2008).
1.1.5. Classification and prognostic factors of CLL
1.1.5.1. Clinical classification and its impact on prognosis
Clinical staging systems are based on lymphadenopathy, organomegaly, platelet and haemoglobin
values. Binet and Rai have developed staging systems that have an important influence on treatment
decisions and prognosis (Rai et al. 1975; Binet et al. 1981). These staging systems are simple and
reproducible. Rai’s system is based on five stages, whereas Binet’s system is based on three classes.
Both of them are in clinical use, the Rai system mainly in North America and the Binet system in
Europe.
Table 2. The Rai staging system for CLL (Rai et al. 1975).
Stage Risk group Clinical findings Median survival (months)
0 Low Lymphocytosis > 5x109/l >150
I Medium Stage 0 + lymphadenopathy 101
II Medium Stage 0 + splenomegaly or
hepatomegaly
71
III High Stage 0 + anaemia <110g/l 19
IV High Stage 0 + thrombocytopenia
<100x109/l
19
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Table 3. The Binet staging system for CLL (Binet et al. 1981).
Class Risk group Clinical findings Median survival
(months)
A Low Lymphocytosis >5x109/l
and < 3 sites
lymphadenopathy*
not reached
B Medium 3 > sites lymphadenopathy 84
C High anaemia and/or
thrombocytopenia
24
*Note: Five possible nodal sites: neck, axillary, inguinal, spleen, liver.
1.1.5.2. Morphological classification and its impact on prognosis
A typical CLL cell is a small lymphocyte, usually with a round nucleus and condensate chromatin.
The mitotic activity is low. The proportion of prolymphocytes is normally less than 2%. A
prolymphocyte count of higher than 2% (CLL/PL), or atypical cell morphology (CLL/mix),
correlates with more aggressive disease. In a case where the prolymphocyte count is over 55%, the
diagnosis is prolymphocytic leukaemia rather than CLL (Swerdlow et al. 2008).
Bone marrow involvements are defined as interstitial, nodular or diffuse. The life
expectancy of patients with a diffuse bone marrow infiltration pattern is significantly shorter than
that of those with non-diffuse patterns (Swerdlow et al. 2008).
1.1.5.3. Biological markers of CLL and their prognostic impact
Molecular and cellular markers that could predict disease progression have been identified. In
particular, the mutational profile of immunoglobulin genes, surface antigens and some cytogenetic
abnormalities show a strong prognostic value.
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1.1.5.3.1. Classification and prognostic impact of chromosomal abnormalities
Fluorescence in situ hybridisation (FISH) has enabled a precise approach to evaluating genetic
abnormalities in CLL. Chromosomal aberrations are common in CLL, as demonstrated in Table 4.
Over  80%  of  the  patients  have  aberrations  in  the  genome,  and  as  many  as  29%  of  patients  have
multiple rearrangements (Döhner et al. 2000; Krober et al. 2002).
Table 4. The incidence of the most usual chromosomal aberrations in CLL patients (Döhner et al.
2000).
Chromosomal aberration % of CLL patients
13q deletion 55%
11q deletion 18%
12q trisomy 16%
17p deletion 7%
6q deletion 6%
8q trisomy 5%
t(14q32) 4%
3q trisomy 3%
The  most  common  aberrations  are  13q  deletion,  which  corresponds  to  a  more
favourable course of disease (Döhner et al. 2000). Two microRNA genes, miR-15a and miR-16-1,
are located in the 13q region (Calin et al. 2002). These microRNA gene products inhibit Bcl2
translation, and  deletion in the 13q region therefore leads to the accumulation of Bcl2 (Calin et al.
2007).
The deletion of 11q corresponds with faster disease progression and extensive
lymphadenopathy and splenomegaly (Döhner et al. 2000). Five-year survival in 11q deletion has
been found to be roughly 70% compared to the 95% in 13q deletion (Döhner et al. 2000). The 11q
deletions are associated to ATM mutations, which lead to more advance disease (Austen et al.
2005).
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The 12q trisomy is a quite frequent aberration in CLL, found in approximately 15% of
patients (Döhner et al. 2000). Trisomy 12 does not increase the progression of the disease and the
survival prognosis is good.
Patients with deletion in the 17p region suffer from more advanced disease than
others. The estimated median survival time from the date of diagnosis is 32 months (Döhner et al.
2000; Krober et al. 2002). The patients are also more symptomatic: they are more likely to
experience fever, night sweats and, weight loss and they have a lower blood count (other than
lymphocytes) (Dohner et al. 2000). The gene of the p53 protein is locates in chromosome 17p.
Among CLL patients with 17p deletion, the majority (over 80%) also have a mutation in the p53
protein, leading to drug resistance and more advance disease (Zenz et al. 2008a; Zenz et al. 2008b).
1.1.5.3.2. Classification and prognostic impact of leukaemic cell surface
antigens
The B lymphocytes surface antigens are revealed by flow cytometry. The clonality of the CLL cells
is investigated from the surface antigens: the CLL B lymphocyte represents either kappa or lambda
immunoglobulin light chains, whereas a normal B lymphocyte expresses both (Hallek et al. 2008).
The typical surface antigens in the CLL cells facilitate the differentiation of the CLL cell from
normal B lymphocytes and other lymphoproliferative malignancies. The CLL B lymphocytes
typically express the CD5, CD19 and CD23 antigens, with weak expressions also of surface
immunoglobulin (Ig) M or D, CD20, CD22, FMC7 and CD79b (Swerdlow et al. 2008).
In clinical use, the most valuable prognostic surface antigen is CD38. It is a
transmembrane glycoprotein and only part of the CLL cells express CD38. An increased proportion
of CD38-positive CLL cells correlates with more aggressive disease, a higher need for
chemotherapy and a shorter overall survival (Krober et al. 2002; Hock et al. 2009; Van Bockstaele
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et al. 2009). The unsolved question is what level of CD38 expression should be regarded as positive
– 5%, 7%, 10% or 30% (Hamblin 2006a).
Another potential prognostic surface antigen is adhesion molecule CD49d, which is
observed in patients with advanced disease. It is associated with the need for treatment and shorter
overall survival (Van Bockstaele et al. 2009).
1.1.5.3.3. Classification of immunoglobulin variable region mutations and
their impact
The mutation status of the immunoglobulin heavy chain variable (IgHV) segment is the most
powerful prognostic marker of CLL outcome, but the measurement is problematic. The mutation
status of the IgHV segment is measured by sequencing the DNA and comparing it to international
databases. This assay is both expensive and labour-intensive, precluding its routine use.
The B cell response to antigen stimulation is mediated through the B cell receptor
(BCR). In normal B lymphocytes the diversity of the BCR is developed in germinal centres. BCR is
combined from two heavy chains and two light chains, each of which are combined from variable
(V), diversity (D) and joining (J) segments. During B cell maturation, the genes of these V, D and J
segments are altered to somatic hypermutations in germinal centres, thus leading to a huge diversity
of receptors.
This maturation can be measured from the proportion of mutated genes in the IgHV
segments in comparison to the baseline database. If the IgHV genes differ from the baseline
database by more than 2%, the definition is mutated IgHV, and if the IgHV genes differ by less than
2% from the baseline database, the definition is unmutated IgHV.
The IgHV mutation status divides CLL patients into two groups that are almost equal
in  size.  The  prognosis  of  the  unmutated  IgHV  CLL  (UM-CLL)  patients  is  worse  than  that  of
mutated IgHV CLL (M-CLL) patients. The median survival for UM-CLL has been determined as
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117 months and for M-CLL 293 months (Hamblin et al. 1999). An exception to this generalization
is made by a small group of M-CLL patients who have a mutation in the IgHV3-21 region; this
leads to aggressive disease (Tobin et al. 2002).
Researchers have searched for a surrogate for IgHV mutation status (as a prognostic
marker in CLL), and intracellular tyrosine kinase ZAP-70 has been proposed as the most reliable
candidate, although it is rather a supplemental factor than a surrogate one. Most of the mutated
cases are ZAP-70-negative and most of the unmutated ones ZAP-70-positive (Wiestner et al. 2003;
Orchard et al. 2004; Kipps 2007). On the other hand, ZAP-70-positive cases can be categorized into
the high-risk group, ZAP-70-negative and IgHV-unmutated cases into the intermediate-risk group
and ZAP-70 negative and IgHV-mutated cases into the low-risk group (Grippen 2008).
The ratio of lipoprotein lipase (LPL) as well as disintegrin and metalloproteinase 29
(ADAM29) mRNA has also been found to be a surrogate for IgHV mutation status. The
LPL/ADAM29 ratio has been found to show 90% concordance with the mutation status (Oppezzo
et al. 2005).
1.1.5.3.4. Apoptosis-associated proteins and microRNA
Accumulation of the B cells is typical for CLL progression. For many years, CLL was considered to
be a disease of failed apoptosis, resulting in the accumulation of long-lived lymphocytes. However,
a recent study has demonstrated that CLL is also a dynamic disease with significant amounts of
proliferation and leukaemia cell turnover every day (Messmer et al. 2005).
The molecular mechanisms that regulate apoptosis in CLL are complex. The BCL2
protein family is one of most important and researched aspects of apoptosis in CLL. Overexpression
of the BCL2 protein has been detected in CLL cells, leading to apoptosis resistance (Schena et al.
1992; Pepper et al. 1997).
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Micro-RNAs (miRNA) are small non-coding RNA particles, which regulate mRNA
translation.  It  has  been  shown  that  two  miRNAs,  miR-15  and  miR-16,  are  deleted  or  down-
regulated in many CLL patients – both of these miRNAs negatively regulate Bcl2 at the post-
transcriptional level (Nicoloso et al. 2007). Both of them are located in the chromosome 13q area,
and the deletion 13q, which is common in CLL, is therefore related to the down-regulation of these
miRNAs (Calin et al. 2002). Low expression of miR-29c and miR233 is associated with more
aggressive disease and early treatments in CLL (Stamatopoulos et al. 2009). The miR-29
microRNA  is  connected  to  the  negative  regulation  of  the  expression  of  the  Mcl1  and  Tcl1
oncogenes (Calin et al. 2007; Stamatopoulos et al. 2009).
The p53 protein is a tumour suppressor protein which causes cell arrest in the case of
DNA damage until the damage is either repaired or leads the cell to the apoptosis if DNA damage
cannot be repaired. Mutation in this protein leads to a resistance to apoptosis and causes multidrug
resistance. The CLL p53 mutation is strongly associated with chromosome 17p deletion, which is a
marker of poor prognosis (Zenz et al. 2008b).
1.1.5.3.5. Other biological prognostic markers
Lymphocyte doubling time (LDT) is defined as the number of months it takes the absolute
lymphocyte count to double in number. Patients with an LDT of 12 months or less have a
significantly shorter overall and treatment-free survival than patients with a LDT of more than 12
months (Swerdlow et al. 2008; Van Bockstaele et al. 2009).
Soluble surface antigens, such as soluble CD23 (sCD23), have been connected to
more advanced disease (Van Bockstaele et al. 2009). Moreover, the short doubling time (less than
one year) of the sCD23 level has been associated with more aggressive disease (Meuleman et al.
2008).
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The lactate dehydrogenase (LDH) level is normally low in CLL, although it is
commonly elevated in many haematological malignancies. Elevated LDH is a marker of advanced
disease in CLL (Van Bockstaele et al. 2009).
Serum beta 2 microglobulin (B2M) is a laboratory parameter that correlates with
clinical outcome, the bone marrow infiltration degree and bulky disease. High (>3.5 mg/L) B2M
levels are associated with a worse prognosis (Shanafelt 2009).
Thymidine kinase (TK) is a cellular enzyme found in dividing cells that is absent in
resting  cells.  Elevated  serum  TK  levels  are  associated  with  disease  progression.  Serum  TK  level
determination is performed with an immuno assay, which is why it has not been adopted in routine
clinical usage (Van Bockstaele et al. 2009).
The prognosis for chemoresistant patients is poor. The chemoresistance mainly
develops  as  a  result  of  chemotherapy,  but  untreated  patients  may  also  be  chemoresistant.  The
median survival for fludarabine-resistant patients has been found to be ten months (Keating et al.
2002).
1.1.6. Treatment and outcome
Although in the case of most cancers, early detection and thus early treatment are essential in
improving outcome, CLL is rarely treated at diagnosis. Normally, treatments are initiated after the
first symptoms appear or in the case of aggressive disease. This treatment model is mainly based on
the results of investigations that have compared early and late treatment, demonstrating no benefit
from early treatment (CLL Trialists' Collaborative Group 1999).
The aims for the treatment in early-stage disease are relative, and the decision to treat
should be made individually. The period of watchful waiting provides more information on a
patient’s disease and assists in the decision-making regarding treatments. Patients in an early stage
(Binet A or B) should not be treated without symptoms, whereas patients in an advance stage (Binet
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C) should be treated. The main symptoms for treatment are i) enlargement of lymph nodes, such as
cosmetically unpleasant lymph nodes in the neck, or enlargement of the spleen; ii) bone marrow
failure, such as in the case of anaemia, neutropenia or thrombocytopenia; iii) progressive
lymphocytosis, where the increase in lymphocytes exceeds the rate of 50% in two months or where
the lymphocytic doubling time (LDT) is less than six months; and iv) disturbing general symptoms,
such as fatigue, night sweating or weight loss (Hallek et al. 2008).
Over the past decades, chlorambucil with or without prednisolon has been widely used
as a first-line therapy in CLL. Currently, chlorambucil is used for the older patients and those who
are not candidates for more intensive treatment (Dighiero and Hamblin 2008). The nucleoside
analogues fludarabine and chlorodeoxyadenosine are the most powerful drugs in CLL, and
fludarabine is the most frequently used chemotherapy agent. In the investigations, fludarabine has
been combined with cyclophosphamide with better results than monotherapy (Catovsky et al. 2007),
even if the overall survival has not increased. Monoclonal antibodies are new therapeutics which
are used as a concomitant therapy with fludarabine, with or without cyclophosphamide. The
monoclonal anti-CD20 antibody, rituximab, combined with fludarabine and cyclophosphamide, has
yielded encouraging results as a first-line therapy (Tam et al. 2008). Furthermore, the monoclonal
anti-CD52 antibody alemtuzumab alone or combined with other chemotherapy agents has
confirmed good results (Gribben and Hallek 2009). The side effects of these monoclonal antibodies
include infections, specifically cytomegalovirus and herpes virus infections, as well as
Pneumocystis carinii pneumonia, myelosupression, fever, skin rash and hypotension (Motta et al.
2009).
Autologous and allogeneic stem cell transplantation can be used in a chemoresistance
situation. Allogeneic transplantation might reach a curative result, but autologous transplantation is
only a palliative treatment (Dreger 2009). Long-term progression-free survival can be achieved in
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30%–60% of transplanted poor prognosis patients by means of allogeneic transplantation (Dreger
2009).
The common problem in every treatment modality is the drug resistance that is
reached at least after chemotherapy.
1.2. Chemo- and irradiation therapy and drug resistance in
chronic lymphocytic leukaemia
1.2.1. The used experimental drug and irradiation treatments and their
mechanism of action
1.2.1.1. Chlorambucil
Chlorambucil is one of the first drugs used in the treatment of cancer. It is mainly used in CLL. In
the past, chlorambucil was a cornerstone in the treatment of the CLL, but currently it has been
mostly replaced by fludarabine as a first-line therapy (Dighiero and Hamblin 2008). It is a
bifunctional alkylating agent of the nitrogen mustard type.
Mechanism: As an alkylator, chlorambucil is an agent that transfers an alkyl group to another
molecule (Kundu et al. 1994). Bifunctional alkylating agents have two reactive alkyl groups that
can  make  two  reactions  with  other  molecules,  such  as  cells,  DNA  and  proteins.  Chlorambucil  is
transported into cells by carrier-mediated systems. The main mechanism of action or toxic action is
thought to be due its ability to form cross-links between DNA strands, which prevents DNA
replication and transcription and thus causes apoptosis. The main resistance mechanisms to
chlorambucil are enhanced DNA repair mechanism (Panasci et al. 2001), inactivation by enhanced
levels of glutathiones or metallothioneins and impaired apoptosis (Morrow et al. 1998).
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1.2.1.2. Verapamil
Verapamil is a calcium channel blocker of the phenylalkylamine class. It is mainly used in the
treatment of hypertension, angina pectoris, cardiac arrhythmia and cluster headaches, and as
preventive medication for migraine.
Mechanism: Verapamil’s mechanism of action is to block voltage-dependent calcium channels. It
also has an ability to block P-glycoprotein, which is a selective drug efflux pump causing
multidrug-resistance in cancer cells. Verapamil alone is toxic and potentiates the effect of
vincristine and anthracyclines against chronic lymphocytic leukaemia in vitro (Vilpo et al. 2000a).
Verapamil has also been shown to have cytoreductive potential in vivo (Berrebi et al. 1994). The
Verapamil cell-killing mechanism may result from disturbed calcium metabolism (Vilpo et al.
2000a).
1.2.1.3. Cyclosporin A
Cyclosporin A is an immunosuppressant drug. It was discovered 1972 and it is
produced by the two fungi Thricoderma polysporum and Cylindrocarpon lucidum (Laupacis et al.
1982). It is widely used in post-transplant medicine and the treatment of many autoimmune
diseases.  Cyclosporin  A  is  not  commonly  used  in  CLL,  but  it  might  be  used  in  the  case  of  an
autoimmune disease, such as autoimmune anaemia, to prevent drug efflux in multidrug resistance
and to attempt to kill CLL cells (Koski et al. 2000).
Mechanism: In a normal immunological defence system, cyclosporin A has a very selective
inhibitory effect on T lymphocytes, suppressing the early cellular response to antigenic and
regulatory stimuli. The consequence of cyclosporin A binding to its receptor is the inhibition of
calcineurin activity and suppression of calcineurin-stimulated effects. This leads to the inhibition of
T-cell activation-associated genes, including the one for interleukin-2, certain proto-oncogenes, and
those for cytokine receptors (Rao 1995). Cyclosporin A also prevents the P-glycoprotein-dependent
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drug efflux pump, therefore potentiating the effect of vincristine and anthracyclines (Consoli et al.
2002).
1.2.1.4. Vincristine
Vincristine is a vinca alkaloid from the Catharanthus roseus plant. It is used in cancer
chemotherapy.
Mechanism: The known mechanism of action for Vincristine has been related to the inhibition of
microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase
stage. Even if CLL cells are not mitotically active, the susceptibility of CLL cells to vincristine in
vitro  has  been  demonstrated.  Interestingly,  CLL cells  are  much more  sensitive  to  vincristine  than
normal lymphocytes (Vilpo and Vilpo 1996; Vilpo et al. 2000b).
1.2.1.5. Fludarabine
Fludarabine is an antimetabolite which belongs to a nucleoside analogy group. It is used as a first-
line therapy in CLL (Dighiero and Hamblin 2008).
Mechanism: Fludarabine is taken up by cells through the nucleoside transporter mechanism and
converted by cellular enzymes to the active metabolite F-ara-ATP, the triphosphate of fludarabine.
The rate-limiting enzymes for this phosphorylation are cellular kinases; hence, fludarabine
accumulates  mainly  in  cells  with  a  high  activity  of  these  enzymes,  such  as  lymphocytes.  In
proliferating cells, F-ara-ATP is actively incorporated into DNA by DNA polymerases during
replication (Fidias et al. 1996). This incorporation causes the termination of the new DNA strand
synthesis at the sites of drug incorporation, including the steps required in the DNA repair process,
and it is closely connected with the drug’s cytotoxic activity (Yamauchi et al. 2001). Fludarabine is
also incorporated into RNA and causes premature termination of the RNA transcripts. Inhibition of
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the RNA transcription may be the major mechanism of action in quiescent CLL cells (Huang et al.
2000).
1.2.1.6. Chlorodeoxyadenosine
Like fludarabine, chlorodeoxyadenosine (CDA) belongs to a nucleoside analogy group. They have
structural, pharmacological and biological similarities. CDA is mainly used in the treatment of
lymphoproliferative malignancies, such as CLL (Robak 2001), and it is mainly used in combination
with cyclophosphamide.
Mechanism: CDA is transported into the cell by the nucleoside transporter mechanism and, in
order to be activated, CDA is phosphorylated within the cell by nucleoside kinases, which are
highly active in lymphocytes. CDA inhibits both cellular ribonucleotide reductase and DNA
synthesis and is incorporated into cellular DNA during replication, causing the termination of new
DNA strand synthesis at the sites of drug incorporation  (O'Brien et al. 1994; Hentosh and Tibudan
1997; Yuh et al. 1998). CDA is able to inhibit DNA repair, which leads to the accumulation of
DNA strand breaks and, moreover, to apoptosis.
1.2.1.7. Doxorubicine
Doxorubicine, adriamycin, is an anthracycline antibiotic. It was initially isolated from Streptomyces
caesius bacteria in the 1950s. It is commonly used as an additional component of chemotherapy in
the treatment of leukaemia and lymphoma but also many other cancers.
Mechanism: There  is  still  some  controversy  about  the  mechanism  of  action  with  regard  to
doxorubicine. The anticancer activity or cytotoxic effects have been proposed to be due to the
following mechanisms: 1) intercalation into DNA, leading to inhibited synthesis of
macromolecules; 2) generation of free radicals, leading to DNA damage or lipid peroxidation; 3)
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DNA binding and alkylation; 4) DNA cross-linking; 5) interference with DNA unwinding or DNA
strand separation and helicase activity; 6) direct membrane effects; 7) initiation of DNA damage via
inhibition of topoisomerase II; and 8) induction of apoptosis in response to topoisomerase II
inhibition (Binaschi et al. 2001; Minotti et al. 2004).
1.2.1.8. Prednisolon
Prednisolon is a steroid hormone. It is widely used as an anti-inflammatory and immunosuppressant
agent.
Mechanism: As a lipophilic, prednisolon diffuses across the cell membrane passively and adheres
to the nuclear receptor in the cytoplasm. The receptor translocates to the nucleus upon ligand
activation, where it can cause regulation of the gene expressions (De Bosscher et al. 2003;
Lowenberg et al. 2008). Inflammatory mediators constitute the gene group that is the most regulated
by prednisolon, but it can also cause the activation of apoptosis cascade. The ability of prednisolon
to cause lymphocyte apoptosis p53 independently in CLL is the main reason for its usage, but it is
also used to treat autoimmune cytopenias (Tsimberidou and Keating 2009).
1.2.1.9. Cisplatin
Cisplatin is a platinum-based compound. It is widely used in the treatment of many cancers, mostly
solid tumours.
Mechanism: It diffuses across the cellular membrane and accumulates in the cell, where its
chloride atoms are replaced by water molecules, thereby transforming cisplatin into a very reactive
mode. The main mechanisms of action are either intrastrand or interstrand DNA strand gross-links.
DNA and protein gross-links have also been described. The cytotoxic effect is thought to be
mediated by platinum-DNA adducts that inhibit DNA replication and transcription. Several cellular
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pathways are activated in response to DNA-cisplatin and DNA-protein interactions, which include
repair proteins, translesion synthesis by polymerases, and induction of apoptosis. The apoptotic
process is regulated by the activation of caspases, the p53 gene, and several pro-apoptotic and anti-
apoptotic proteins. This kind of cellular processing eventually leads to an inhibition of the
replication or transcription machinery of the cell (Ahmad 2010). Cisplatin is not commonly used in
the treatment of CLL.
1.2.1.10. The use of gamma and UV irradiation
Gamma irradiation is widely used in cancer therapy. In CLL it is used as a concomitant therapy,
such as decreasing size of the spleen or the lymph nodes.
Mechanism: Gamma irradiation causes cell damage by the formation of single- or double-strand
DNA breaks (Elkind 1985), the former being repairable but the latter being lethal to the cell
(Myllyperkio et al. 1999). The DSB/SSB induction ratios are roughly 1:20 for ionizing irradiation.
UV irradiation is not in clinical use as a cancer treatment, but rather in investigative
use.
Mechanism: UV irradiation induces DNA cross-links and DNA single-strand breaks which are
normally repaired by the nucleotide excision repair system. First, this repair system excises the
damaged site and then creates a new strand. UV irradiation has been used to investigate these repair
systems (Vilpo et al. 1995; Myllyperkio et al. 1999).
1.2.2. Mechanism of the drug resistance
Drug resistance is a major problem in cancer treatment. The mechanisms of drug resistance have
been investigated extensively with poor clinical results. Insight into the cellular resistance
mechanisms holds the promise of leading to better treatments for cancer patients. Resistance
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mechanisms can be divided into two groups. The first of these appears in the case of A) an altered
intracellular concentration of the drug, which is mainly meant to enhance their extrusion from the
cell. The second group involves B) the required activation of the drugs once inside the cell – this
can be i) impaired by the loss of specific enzymatic activities involved in their metabolic activation;
but ii) certain agents can also be enzymatically inactivated; iii) cellular targets can be altered, either
by increased or decreased expression levels, or by mutations; and, finally, iv) once the cellular
target of the drug is damaged, resistance factors can attenuate the capacity of a cell to undergo
apoptosis.
1.2.2.1. Drug-resistance-related proteins and enzymes
P-glycoproteins. In humans several P-glycoproteins have been identified. The most widely known
P-glycoprotein, p170, is produced by the MDR-1 gene. P-glycoproteins are large transmembrane
proteins that act as an energy-dependent efflux pump for physiological substrate steroids, hormones
and bilirubin and cytotoxic agents. The main substrates in malignant cells are anthracyclines, vinca
alkaloids and epipodophyllotoxins. Overexpression of p170 causes reduced intracellular
concentrations of drugs that are substrates for p170, thus inducing multidrug resistance (MDR). It is
frequently observed in leukaemia and lymphomas (Ambudkar et al. 1999; Ambudkar et al. 2003).
In many haematological malignancies, the elevated expression of an MDR phenotype is a
consequence of exposure to cytotoxic drugs (Webb et al. 1998). In CLL lymphocytes, the
expression of p170 has been shown to be elevated (Burger et al. 1994).
The function of the P-glycoproteins can be modulated in vitro by  Verapamil  and
Cyclosporin A (Vilpo et al. 2000a; Consoli et al. 2002). The problem is that effective concentrations
required to modulate p-glycoprotein activity are easily above the normal therapeutic dose.
MDR-related proteins (MRP) are an ATP-dependent transmembrane transporter
protein family. This family is comprised of nine transporters that are able to transport structurally
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diverse lipophilic anions and function as drug efflux pumps. MRP has similar transport specificity
to MDR, but drugs are frequently conjugated with glutathione and other anions, or they are co-
transported with glutathione (Ambudkar et al. 2003). MRPs have been connected to resistance to
anthracyclines, vinca alkaloids, epipodophyllotoxins, camptothecins and methotrexate (Kruh and
Belinsky 2003).
In CLL only a small group of patients express MPR proteins before treatment, but
after anticancer drug therapy the proportion increases significantly (Webb et al. 1998).
Glutathione (GSH) is a major intracellular reducing agent. Two important pathways
utilise glutathione: 1) free radical neutralisation, either spontaneous or catalysed by glutathione s-
transferase which is important for xenobiotic detoxification, 2) the reduction of peroxides, such as
hydrogen peroxides or lipid peroxides and disulphide bonds (Estrela et al. 2006). An increased level
of glutathione may decrease the anticancer drug concentration in the cell and thus lead to drug
resistance, whereas a decreased cellular concentration of glutathione potentiates the anticancer drug
effect (Hagrman et al. 2004). The intracellular concentration of glutathione has been demonstrated
to be higher in CLL lymphocytes than normal lymphocytes (Ferraris et al. 1994). The depletion of
GSH in sensitising cells to ionising radiation has been demonstrated in lymphoid cell lines
(Dethmers and Meister 1981).
Glutathione s-transferases (GST) are multifunctional proteins that protect cells
against carcinogens and many other toxins. GST conjugates glutathione with a wide variety of
hydrophobic and electrophilic compounds, and this facilitates the elimination of the xenobiotics,
since the resulting metabolites are more water-soluble (Hayes et al. 2005). Several antineoplastic
drugs, particularly the reactive electrophilic alkylating agents, can form conjugates with glutathione
both spontaneously and in GST-catalysed reactions, thereby detoxifying them (Dirven et al. 1994).
GST expression levels in normal and CLL lymphocytes vary on an individual basis,
but there are no significant differences. Lymphocytes from chlorambucil-resistant patients have
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been reported to be subject to a twofold increase in GST activity when compared to the
lymphocytes of untreated patients (Schisselbauer et al. 1990). However, glutathione-conjugated
chlorambucil is more water-soluble and therefore less permeable to the plasma membrane, which is
why it needs to be transferred across the plasma membrane by an efflux mechanism (Morrow et al.
1998; Ballatori et al. 2009). Therefore, not only one mechanism alone but rather a complex of
mechanisms achieves drug resistance.
Metallothioneins are a group of small intracellular proteins with the capacity to bind
metal ions strongly, mainly zinc in physical conditions. Several functions of metallothionein have
been described: free radical neutralisation, inflammation regulation, regulation of zinc-containing
proteins (like p53), DNA damage and cell death regulation following a number of pathological
conditions, and protection of cells against various forms of stress, such as oxidative injury,
radiation, chemotherapy and metal toxins (Pedersen et al. 2009).
The metallothioneins’ zinc ion can be easily displaced by metal ions that have a high
affinity for thiolates. In this way, metallothioneins serve as a detoxifying protein for toxic metal
ions that may enter the cell. Increased metallothionein levels seem to decrease active anticancer
drug concentrations and therefore contribute to drug resistance (Hagrman et al. 2003). Increased
expressions of metallothioneins have been reported in various cancers (Pedersen et al. 2009).
Topoisomerases are intranuclear enzymes that modify DNA strands during the
transcription, replication and chromosome segregation. Topoisomerases are classified as type I or
type II according to their ability to introduce transient breaks in the proteins linked in one or both
strands of the double helix (Nitiss 2009a). Drugs targeting topoisomerase II are divided into two
classes; A) an increased level of topoisomerase II-DNA covalent complexes which lead to DNA
strand breaks and, therefore, apoptosis, and B) the elimination of the essential enzymatic activity of
topoisomerase  II,  which  leads  to  the  catalytic  inhibition  of  the  cell  and,  therefore,  apoptosis.
Sensitivity to topoisomerase-II-targeting drugs depends on i) the levels of topoisomerase II protein
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and ii) qualitative changes in topoisomerase II enzymes which decreases the topoisomerase-drug
complex formation (Danks et al. 1987). Cells overexpressing topoisomerases are hypersensitive to
topoisomerase-dependent drugs, while cells expressing low levels of topoisomerases are relatively
drug resistant (Nitiss 2009b). Topoisomerase II is the target of certain classes of antineoplastic
agents, including anthracyclines, epipodophyllotoxins, amsacrine, and other intercalating agents.
In CLL the expression level of the topoisomerase II protein, mRNA and catalytic
active has been found very low (Potmesil et al. 1987; Beck et al. 1996; Valkov and Sullivan 1997).
This suggests a natural resistance of CLL to topoisomerase-II-affecting drugs.
1.2.2.2. Apoptosis-associated proteins
If the chemotherapeutic agent eventually manages to damage DNA permanently, the
programmed cell death cascade is activated, leading the cell to apoptosis. The apoptosis cascade is a
complex pathway of a multitude of regulated processes. The p53 protein regulates the expression of
many apoptosis associated genes, with the Bcl2 protein family in particular. The Bcl2 protein
family, consisting of both pro- and anti-apoptotic proteins, regulates mitochondrial membrane
potential and, moreover, regulates cytochrome C release to cytoplasm. Finally, cytochrome C
activates the caspases cascade which leads to the splitting of the DNA and major cell structures and,
finally, to apoptosis (Burz et al. 2009).
In CLL the expression of apoptosis-associated proteins is increased in comparison to
normal lymphocytes. Especially the Bcl2 protein has been identified as up-regulated in CLL
(Schena et al. 1992; Pepper et al. 1997).
Bcl2 is an anti-apoptotic protein and causes resistance to chemotherapeutic agents
(Johnston et al. 1997; Pepper et al. 1997; Thomas et al. 2000). The Bax protein belongs to the Bcl2
protein family, but its effect is pro-apoptotic. Underexpression of Bax leads to delayed apoptosis
and can cause drug resistance (Bosanquet et al. 2002). Even more so than Bcl2 or Bax alone, the
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Bcl2/Bax ratio has been implicated as a marker of chemoresistance in CLL (Pepper et al. 1997;
Pepper et al. 1998; Pepper et al. 2001).
Bcl2l1, Bcl2a1 and Mcl1 (myeloid cell leukaemia sequence 1) belong to the Bcl2-
associated family and suppress apoptosis in a pathway common to Bcl2 (Burz et al. 2009). High
Mcl1 expression has been connected to a failure to achieve a good treatment response in CLL
(Saxena et al. 2004).
Death-associated protein kinase 1 (Dapk1). Most normal cells require adhesion to the
correct extra-cellular matrix for survival, and inadequate or inappropriate cell–matrix interaction
often causes apoptosis. One of the main negative mediators of these interactions is Dapk1.
Activation of this kinase leads to the activation of a p53-dependent apoptosis cascade (Bialik and
Kimchi 2006). The expression of Dapk1 is downregulated in CLL (Raval et al. 2007).
Myc is a DNA-binding phosphoprotein that regulates transcription, and it can regulate
both proliferation and apoptosis. Myc drives cells into apoptosis via several mechanisms – e.g., via
the action of P53 and Bax and by inducing susceptibility to tumour necrosis factor-a (TNF-a).
Deregulation of the Myc oncogene has been shown to play a critical role in pathogenesis of many
lymphomas (Klapproth and Wirth 2010). It is expressed normally in most of CLL cases, but Myc
overexpression leads to aggressive disease (Huh et al. 2008).
The p53 protein acts as an activator of the apoptosis signalling pathway. It
upregulates the proapoptotic genes Bax and Bak via the Puma protein. It is also able to downegulate
the antiapoptotic Bcl2 protein family, with Bcl2 in particular. The p53 protein is inactivated in most
human cancers and plays a certain role in drug resistance (Chari et al. 2009). The molecular
alterations can result in either high levels of a mutated (inactive) p53 protein or a complete absence
of the p53 protein. In CLL p53 is mutated in 15%–20% of patients (Cordone et al. 1998) and
mutation is associated with chromosome 17p deletion, although mutations in the absence of 17p
deletion  are  also  seen.  This  mutation  decreases  the  activity  of  the  p53  protein  and  leads  to  a
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resistance to apoptosis, thereby inciting more aggressive disease and drug resistance (Zenz et al.
2008b).
The ataxia telangiactasia mutated (ATM) is a protein kinase that coordinates an
integrated cellular response to DNA damage in the form of double-stranded DNA breaks. The main
target of the ATM is to activate the p53 protein (Shiloh 2003). Mutations in the ATM gene have
been found in 12% of CLL cells, and reduced overall and treatment-free survival has been observed
in patients with ATM mutations (Austen et al. 2005).
1.2.2.3. DNA repair molecules
Most of the chemotherapeutic agents exert their action via DNA damage – i.e. DNA strand breaks,
cross links or incorporated nucleoside analogues. The repair of DNA damage before the initiation of
signalling pathways that induce programmed cell death, apoptosis, represents a cause of drug
resistance. The repair mechanisms can be divided into the following groups: i) direct reversal of
damage, ii) base excision repair, iii) nucleotide excision repair (NER), iv) mismatch repair, v) repair
of cross-links (NHEJ), and vi) double strand break repair (Puranen 2007).
The activity of the NER process in CLL lymphocytes has been found equal in
chlorambucil-pretreated and untreated patients (Bramson et al. 1995). Furthermore NER activity
has  been  demonstrated  to  be  low in  most  of  CLL lymphocytes  (Barret  et  al.  1996),  and  the  NER
process after UV induction seems to be more active in normal lymphocytes than CLL lymphocytes
(Myllyperkio et al. 2000). The DNA-PK protein is a key component in the NHEJ process. Low
levels of DNA-PK have been associated with the sensitivity to chemotherapy in CLL cells, whereas
increases in DNA-PK activity have resulted in an increased resistance to chlorambucil (Deriano et
al. 2005; Amrein et al. 2007). Nucleoside analogues, fludarabine and chlorodeoxyadenosine, can be
used as NER inhibitors and thus potentiate the effect of alkylating agents (Bellosillo et al. 1999;
Flinn et al. 2007).
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AIMS OF THE STUDY
In the present study series, the responses to nine drugs and two types of irradiation were evaluated
in  36  CLL  patients.  The  correlations  of  sensitivities  were  analysed  and  factors  predicting  the
responses evaluated.
The specific aims were:
1. to evaluate the multidrug resistance in CLL patients and, specifically, to assess the
significance of previous treatments in drug resistance, in addition to finding correlations
between differently acting drugs (I)
2. to evaluate the impact of surface antigens as prognostics markers of chemo- and irradiation
resistance (II)
3. to compare two groups of CLL patients, evaluating the effect of the IgHV mutation status on
chemotherapy and irradiation responses (III)
4. to evaluate the significance of the expressions of apoptosis-associated genes for
chemotherapy and irradiation responses (IV)
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MATERIALS AND METHODS
3.1. Ethical considerations
The study  protocols  were  approved  by  the  ethical  committee  of  Pirkanmaa Hospital  District.  The
work was carried out according to the Helsinki Declaration. Written informed consent was obtained
from all subjects.
3.2. Materials
3.2.1. Patients and samples
The  samples  for  this  study  series  (I, II, III and IV) were collected from 36 consecutive CLL
patients referred to the CLL outpatient clinic at Tampere University Hospital. Some of the patients
were newly diagnosed cases, and the rest were diagnosed earlier and referred due to changes in the
disease status or for the startup of chemotherarapy. Diagnosis and staging were based on standard
clinical, morphological and immunophenotyping criteria. All patients had a CD19+/CD23+/CD5+
phenotype. All cases had a mature CLL, CLL/mix or CLL/PL morphology. Most patients had
chromosomal aberrations but none indicating other types of chronic lymphoid leukaemia besides
typical CLL. Nine of the 36 patients had previously been treated, and 27 were untreated (Table 5).
Clinical responses were documented in 2010 from 25/36 patients; the rest of subjects were
monitored in other hospitals and the information was not available. Out of these 25 patients, 6 did
not require treatments and 19 were treated as described in Table 5.
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Table 5. Information concerning the investigated patients; treatments before and after leukaemic
cell isolation.
NO MUT YEAR AGE SEX BINET LEUK TREAT HIST CYTOGENETICS CLINICALRESPONSE
1 0 1993 54 m A 66 None M Del 11q, del 13q
99-02 LPx31-PR; 02
FLUx1-NR; 02-03
FLU+CYCx7-CR; 04
FLU+CYCx3+GAM-
PR; 04 GAM-NR
2 1 N 64 m A 72 LP I Del 7q, del 11q N
3 0 1994 72 m B 105 None D 12q trisomy, 11qdel No treatment
4 0 1991 69 m B 108 L I Normal 94 LP-CR; 97 LP-PR
5 1 N 61 f A 90 None I Del 6q N
6 1 1988 50 f A 166 None N Del 13q 96-97 LP-CR; 00LPx3-PR
8 0 N 58 m C 323 LP,6xCO D
Del 17p, trisomia
12 N
9 0 N 68 m B 73 None I Del 6q, del 13q N
10 1 1992 68 m A 56 None M Del 13q No treatment
11 0 1990 68 f C 90 L D Del 11q, del 13q 93 L-PR; 95 LP-PR
12 1 1992 64 m C 135 LP D Del 13q 93 LP-PR
13 1 N 68 m C 168 None M Del 11q, del 13q N
14 0 N 66 f C 190 LP,7xCO D
Add 1p, del 5q, del
10, del 17 N
15 1 1992 57 m A 68 None D Del 13 q 97-99 LPx15-CR; 01-02 Lpx11-PR
16 0 1994 68 m A 87 None I Del 13q 98 LPx43-CR
17 0 N 57 m A 130 None I Del 13 q
96-98 LPx20-CR; 99
LPx 8-PR; 00-01
CHOPx17-PR; 01
GAM-PR; 02 FLUx5-
CR; 02 RITx4-PR; 03
RADx2-PR; 03
FLU+CYC-NR
18 0 1995 73 f C 87 None M 12q trisomy
95-96 LPx8-PR; 97
CHOPx3+GAM-PR;
97 FLUx3-PR
19 0 1996 55 m A 40 None M 12q trisomy, 6ptrisomy, 13 q del
96 LPx4-PR; 97-99
CHOPx15+GAM-PR;
02 FLU+CYCx2-CR
20 0 1996 53 m B 72 None D Normal No treatment
21 1 73 m B 99 None D del 11q No treatment
22 0 1996 55 m B 67 None I del 6q, del 13q
99 FLU-PR; AUTO
STC 00-CR; 04
RIT+CHOPx8+GAM-
PR
23 0 1995 62 m B 62 None M del 11q 97 LPx10-CR
24 0 N 79 f B 97 4xCHOP M Normal N
25 0 N 54 m B 220 None D 12q trisomy, del N
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13q
26 1 N 48 m A 93 None I Normal N
27 1 1995 67 m A 74 None M Del 13q 99-00 LPx10-PR; 01LPx5-PR
28 0 1991 67 m C 183 LP D del 11q
96 LPx6-PR; 97-98
LPx8-PR; 99
CHOPx2-PR
29 0 1997 78 m B 231 None M Translocation 4;11 98-99 L-PR; 00 LPx5-PR
30 0 1996 69 f A 75 None M del 4q, del 16, del17, del 18
00 LP-NR; 00
CHOPx3-PR
31 1 1991 59 m A 106 LP M Normal
94-95 L-PR; 01
LPx15-CR; 04 LPx6-
PR; 05 LPx3-PR
32 0 N 70 m A 147 None D Normal N
33 N N 57 m A 190 None M Normal N
34 N 1979 75 f B 180 None D Normal No treatment
35 0 1992 76 f C 211 None M del 11q 98 Lpx3-PR
36 0 1989 78 f A 158 None I Trisomy 16 No treatment
37 N 1998 63 m C 198 None I Trisomy 12
98-99 LPx15-CR; 02
LPx3-NR; 02 CHOP
x5 NR, 02 FLUx1-
PR; 03FLU+CYCx4-
PR; 03
FLU+CYC+RITx4-
PR
Abbreviations: NO, patient number; MUT, IgHV mutation status, with 0 = no mutation, 1 =
mutation, N = not evaluated; YEAR, year of diagnosis, with N = not known; AGE, age at diagnosis;
SEX, m = male, f = female; BINET, clinical classification by Binet; LEUK, peripheral blood
leukocytes; TREAT, treatment before leukaemic cell isolation, with LP = Leukeran (chlorambucil)
and prednisolon, CHOP = cyclophosphamide- (hydroxydaunorubicin (doxomycin)-
Oncovine(vincristine)-prednisolon; HIST, bone marrow histology, with I = interstitial, N = nodular,
D = diffuce, M = mixed; CYTOGENETICS, cytogenetical variation; CLINICAL RESPONSE,
clinical responses after sample collection, with CR =  complete response, PR = partial response, NR
= no response, FLU = fludarabine, GAM = gamma irradiation, RIT = rituximabi, CYC =
cyclophosphamide, N = not known.
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3.2.2. Isolation of leukaemic cells
Peripheral blood mononuclear cells were isolated from heparinised (Noparin, Novo Nordik,
Dagsvaerd, Denmark) blood samples by means of centrifugation over a Lymphoprep layer
(Nycomed, Oslo, Norway) at a density of 1.077 g/ml. The cells were washed twice with phosphate-
buffered saline (PBS, pH 7.4) and once with a medium consisting of RPMI 1640 (20 mM Hepes,
ICN Biochemicals, Costa Mesa, CA), 10% heat-inactivated foetal calf serum (Gibco BRL, Paisley,
Scotland), 2 mM L-glutamine (Gibco BRL) and antibiotics (Gibco BRL, penicillin, 50 U/ml,
streptomycin, 50 µg/ml). Cell counting was performed by using Technicon H1, H2 or H3 analyzers
(Bayer Diagnostics). The density gradient centrifugation yields – with no other purification steps –
were good (range 29%–92%; mean 61.7%; SD 16.2%, n = 36). This information is necessary for
the interpretation of the results. The proportion of monocytes plus polyclonal T and B lymphocytes
was 1%–13%, indicating that 87%–99% of the isolated cells represented the leukaemic population.
3.3. Methods
3.3.1. The experimental drugs and irradiation used
The following drugs and types of irradiation were used in the present study series (I, II, III and
IV): chlorambucil (Sigma Chemical  Co.,  St.  Louis,  MO); 2-chloro-2’-deoxyadenosine (Sigma);
cyclosporin (Cyclosporin A, Sandoz Pharmaceutical Co., Basle, Switzerland);
cisplatinum(II)diammine-dichloride (cisplatin, Sigma); doxorubicin hydrochloride
(Adriamycin, 2 mg/ml, Pharmacia, Uppsala, Sweden); 2-fluoroadenine-9-beta-D-
arabinofuranoside (fludarabine, Sigma); prednisolon sodium succinate; Di-Adreson-F
(prednisolone, N.V. Organon, Oss, the Netherlands); vincristine (Oncovin, 1mg/ml, vincristine
sulfate, Lilly France SA, Fegersheim, France); verapamil (Verpamil 2.5 mg/ml, Orion Ltd., Espoo,
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Finland); gamma irradiation: 0.007 Gy s-1 (137Cs source; Molsgaard Medical, Denmark); UV-C
irradiation: 1 J m-2 s-1 (UV Unit; Gelman Sci-ences, Ann Arbor, MI).
3.3.2. Cytotoxicity assay by leucine incorporation
The cytotoxic effects of nine drugs and two types of irradiation against peripheral blood
lymphocytes from 36 CLL patients were assessed using 4-day cultures by adding five different
concentrations (0, 2, 10, 50, 250 and 1,250 nmol/l) of test drugs to the cultures in 96-well
microplates. Alternatively, the cells were irradiated by five different doses of ionizing and UV
irradiation. 200,000 cells per well were seeded in a volume of 100 µl (2 x 106 cells  per ml).  The
effects were monitored by assessing protein synthesis using 14C-leucine incorporation. 14C-leucine
(specific activity 1.3 mCi/mmole, 0.5 µCi/ml) was added for the final 24 hours of culture. After
incubation, the proteins were precipitated with 0.2 M perchloric acid and collected on fibreglass
filters using a multiple cell harvester (LKB Wallac 1295-001, Turku, Finland). The radioactivity
incorporated was measured in a liquid scintillation counter (Wallac 1410). ID80 values were
calculated from dose-response curves using duplicate or triplicate assays with 5 drug/irradiation
doses. The ID80 values are doses causing 80% inhibition in cell viability, as measured by means of
14C-leucine incorporation. Previously, good correlation has been demonstrated between the number
of living cells and leucine incorporation in 4-day cultures ex vivo, using the same drugs and types of
irradiation (Vilpo and Vilpo 1996; Vilpo et al. 2000b).
3.3.3. Surface antigens and immunophenotyping by flow cytometry
Immunophenotyping of the all samples was performed by means of flow cytometry (FACSCalibur,
Becton Dickinson Immunocytometry systems, California) using commercial mouse monoclonal
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antibodies and respective immunoglobulin isotype controls. The antibodies used in Study II are
summarised in Table 6.
Table 6. Investigated monoclonal antibodies.
Antigen (source)a Label Isotype control Clone
CD2 (B) FITC ?2a Leu-5b
CD4/CD8 (B) FITC/PE ?1/?2a Leu-3a/leu-2a
CD20 (B) FITC ?1 Leu16
CD45RA (B) FITC ?1 Leu-18
CD45RO (B) PE ?2a Leu-45RO
CD122 (B) PE ?1 Anti-IL-2R-p75
CD19 (B) PE ?1 SJ25C1
CD5 (B) FITC ?2a Leu-1
CD23 (B) PE ?1 Leu-20
FMC7 (I) FITC ? FMC7
CD22 (B) FITC ?2b Leu-14
CD34 (B) PE ?1 8G12
CD38 (B) PE ?1 Leu-17
CD10 (B) FITC ?2a Anti-CALLA
CD124 (I) PE ?1 S4-56C9
CD126 (I) PE ?1 M91
CD11c (D) FITC ?1 KB90
CD14 (D) FITC ?2a TUK4
CD21 (D) FITC ?1 1F8
CD79b (D) FITC ?1 SN8
mIgG (P) FITC ?1 G18-145
mIgD (P) FITC ?2a IA6-2
mIgM (P) PE ?1 G20-127
CD95 (P) FITC ?1 DX2
CD40 (P) FITC ?1 5C3
CD27 (P) FITC ?1 M-T271
CD130 (P) PE ?1 VC041
CD25 (B) FITC ?1 Anti-IL-2R
CD154 (B) PE ?1 Anti-gp39
CD80 (B) PE ?1 Anti-B7
CD45/CD14 (B) FITC/PE ?1/?2b Anti-Hle-1/leu-3M
??? (B) FITC/PE ?1/?1 TB28-2/1-155-2
aAbbreviations: B, Becton Dickinson; D, Dako; I, Immunotech; P, Pharmingen. For a more
accurate description of antigen proteins, see, e.g.,
http://www.ncbi.nlm.nih.gov/sites/entrez?db=Protein&itool=toolbar
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3.3.4. Analysis of the immunoglobulin variable region gene mutation status
by PCR
For Study III, the mutation status of IgHV genes was analysed by means of polymerase chain
reaction (PCR). Because previously received chemotherapy modifies the in vitro chemosensitivity,
analyses were performed only for untreated patients. Additionally, three patients were excluded
because their IgHV gene mutation status could not be determined. The final count of patients
included in the analysis was 24.
Variable (V) gene family-specific (PCR) amplification was performed using six
family-specific  V  primers  and  one  joining  (J)  primer.  The  PCR  amplification  and  the  PCR
conditions have been detailed elsewhere (Li et al. 1999). To distinguish monoclonal PCR products
from polyclonal ones, single-stranded conformation polymorphism analysis was performed using
GenePhor system electrophoresis (Pharmacia Biotech, Uppsala, Sweden), according to the
manufacturer’s instructions. Clonal PCR products from rearrangements were sequenced directly
with Big-Dye Terminator Cycle Sequencing Reaction Kits (Perkin-Elmer, Applied Biosystems,
Foster City, CA, USA). All sequence reactions were analysed using an automated DNA sequencer
(ABI 377, Applied Biosystems, Foster City, CA, USA). The obtained sequences were aligned with
the closest published germline genes using the IgBLAST, the V-BASE and the international IMGT
databases. IgHV gene sequences deviating by more than 2% from the corresponding germline gene
were defined as mutated, whereas sequences displaying less than 2% mutations were considered
unmutated.
3.3.5. Analysis of the apoptosis-associated genes by quantitative RT-PCR
In Study IV, expressions of the apoptosis-associated genes were compared to drug and irradiation
sensitivities. The expressions of the apoptosis-associated genes (Bcl2, Bax, Bcl2l1, Bcl2a1, Mcl1,
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Dapk1, Myc) were analysed by means of quantitative real-time transcription polymerase chain
reaction (QRT-PCR). Gene expression analysis failed in four cases, and the final patient count was
therefore 32.
Total  RNA  was  extracted  using  Trizol  Reagent  (Gibco  BRL,  Grand  Island,  NY,
USA). The RNA samples were treated with DNase I (Boehringer Mannheim, Mannheim, Germany)
to  remove  the  genomic  DNA  contaminating  the  preparations,  following  the  instructions  of  the
manufacturer. The quality and integrity of the RNA were checked by means of electrophoresis
using a 1% agarose gel with ethidium bromide staining and UV transillumination. RNA
concentrations were measured by a spectrophotometer at 260 nm.
The primers and other analytical methods have been described in detail previously
(Nagy et al. 2003). In brief, cDNA was synthesized using 0.5 µg total RNA. PCRs with gene-
specific primers were performed in a LightCycler thermal cycler (Roche). For each cDNA sample,
the PCR was run in duplicate. Standard curves were obtained by means of serial dilutions of the
beta-globulin gene (DNA Control kit, Roche), according to the supplier’s instructions. The
concentration  of  each  gene  product  was  determined  on  the  basis  of  a  kinetic  approach  using
LightCycler software (Roche). The levels of beta-actin were measured and used for the
normalization of RNA quantity and quality differences in all samples.
3.3.6. Statistical analysis
Correlations were calculated using the Spearman’s rank order correlation test. Multiple regression
analyses were carried out using forward stepwise regression. The Mann-Whitney U test was applied
for group comparisons. Statistical analyses were performed using the statistical software package
STATISTICA for Windows (ver. Win 5.1D, 1996 StatSoft, Inc., Tulsa, OK).
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RESULTS
4.1. Multidrug resistance (Study I)
In Study I, sensitivities of nine drugs and two types of irradiation against the
peripheral blood leukaemic cells of 36 CLL patients were compared. These results are based on
2,376 duplicated cultures, with six doses, eleven test agents and 36 patients.
From the tested drugs, chlorodeoxyadenosine and vincristine induced an 80% median
inhibition in leucine incorporation by the lowest concentrations (Figure 1). Moreover, the drugs
requiring the highest concentrations for a similar effect were verapamil and cisplatin. Cyclosporin A
demonstrated the lowest and prednisolon the highest variation in the responses. Furthermore, the
ID80 values for prednisolon could not be determined for all patients, which is why ID50 values
were used. These sensitivity results are mostly in accordance with previously published ones
(Bosanquet and Bell 1996; Bosanquet et al. 2009).
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Figure 1. In vitro sensitivities of the peripheral blood leukaemia cells of 36 CLL patients to nine
drugs and two types of irradiation.
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Abbreviations: CLB, chlorambucil; CDA, chlorodeoxyadenosine; FLU, fludarabine; CIS,
cisplatin; DOX, doxorubicin; PRE, prednisolon; VIN, vincristine; GAM, gamma irradiation; UV,
UV irradiation; CYA, cyclosporine A; VER, verapamil. Median values, ranges, outliers and
extremes are illustrated according to the statistics given on the right side of the figure. The ranges of
outliers and extremes are illustrated in the classic box and whisker plot where the upper box value is
the 75th and the lower box value the 25th percentile. The outlier coefficient is equal to 1.5 and the
extreme coefficient equal to 3. The ID80 values are expressed in microM, with the exception of
gamma irradiation in Gy and UV irradiation in J/M2. The patients with outlier or extreme values are
characterised further in Table 8.
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The extreme and outlier values are separately illustrated in Figure 1. This was our
statistical approach to determine relative cellular drug resistance. Individual cases are discussed in
Table 7.
Out of the 36 patients, 14 were categorised as belonging to the outlier or extreme
group of one or more drugs. Furthermore, 6/9 patients who had previously received chemotherapy
and 8/27 previously untreated patients were categorised into this outlier or extreme group. This
result indicates that the ratio of resistant/sensitive cases in the chemotherapy group was 4.8 times
higher than among the previously and currently untreated patients (P=0.0484, chi2-test, n=36).
The concordance between previous or ongoing drug therapy and in vitro drug
resistance was poor. In three out of the nine cases, the patients had received the same drug to which
he or she had demonstrated drug resistance (Table 7). Subsequent clinical responses for these
outlier and extreme patients were available in 10 of 14 cases (Table 5).  In three out of ten cases,
treatments were not needed, and three out of the remaining seven patients had received the same
drug to which he or she demonstrated drug resistance. Patient no. 18 demonstrated in vitro
resistance against fludarabine, and her clinical response to fludarabine was partial. Patients no. 19
and 22 demonstrated in vitro resistance against doxorubicine and their clinical responses to CHOP
treatment were partial.
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Table 7. Patients with extreme and outlier ID80 values in cytotoxicity testing.
Patient #
(FAB type) Drugs
1 ID80 (mM) Previous treatment 3
2 (CLL) Fludarabine (O) -2 9.5 LP
Chlorambucil (E) + 80.4 LP, 6xCOP, 7xCHOP
2-Chlorodeoxyadenosine (E) - 35
Fludarabine (E) - 22
Doxorubicin (E) + 7.0
8 (CLL/PL)
UV-irradiation (E) - 92
10 (CLL) Chlorambucil (E) - 165 None
2-Chlorodeoxyadenosine (E) - 10
Fludarabine (E) - 34
Doxorubicin (E) - 8.5
11 (CLL) UV-irradiation (E) - 92 L
14 (CLL/PL) 2-Chlorodeoxyadenosine (E) - 10 LP, 7xCOP, 10xCHOP
Fludarabine (E) - 30
15 (CLL) Doxorubicin (O) - 2.6 None
18 (CLL, mix) 2-Chlorodeoxyadenosine (E) - 5.1 None
Fludarabine (E) - 14
19 (CLL/PL) Doxorubicin (E) - 5.3 None
Cyclosporin A( O) - 7.5
20 (CLL/PL) 2-Chlorodeoxyadenosine (E) - 7.1 None
Fludarabine (E) - 19
21 (CLL, mix) Doxorubicin (O) - 3.1 None
22 (CLL/PL) Doxorubicin (E) - 10 None
24 (CLL, mix) 2-Chlorodeoxyadenosine (E) - 6.0  4xCHOP, LP
Fludarabine (O) - 7.0
Doxorubicin (E) + 5.0
Cyclosporin A (O) - 4.4
29 (CLL) Doxorubicin (E) - 10 None
31 (CLL) 2-Chlorodeoxyadenosine (O) - 3.0 LP
Abbreviations: FAB, The French-American-British classification system; 1 E = extreme and O = outlier
(see Figure 1); 2 - = not given previously, + = previously given; 3 L = Leukeran (chlorambucil), P =
prednisolon, CH(O)P = cyclophosphamide-(hydroxydaunorubicin (doxomycin)-
Oncovine(vincristine)-prednisolon.
Multidrug resistance was analysed by using the non-parametric Spearman’s rank order
correlation analysis. The results are illustrated in Table 8. There were strong correlations between i)
chlorambucil and gamma-irradiation, ii) chlorodeoxyadenosine and fludarabine, iii)
chlorodeoxyadenosine and vincristine, iv) chlorodeoxyadenosine and gamma-irradiation, v)
fludarabine and cisplatin, vi) doxorubicin and gamma-irradiation, vii) prednisolon and cyclosporin
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A, as well as viii) vincristine and verapamil. These correlations did not change remarkably if the
nine treated patients were excluded. However, the correlations of treated patients were more
variable: 5/9 demonstrated a stronger correlation, 1/9 a similar correlation and 3/9 a less stringent
correlation than in the total patient group.
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Table 8. Relationships between the cytotoxicity of nine drugs and two types of irradiation in vitro
in cells from 36 CLL patients.
Drug CLB8
0
CDA8
0
FLU8
0
CIS80 DOX8
0
PRE5
0
VIN80 GAM8
0
UV80 CYA8
0
CDA80
0.36
0.030
0
FLU80
0.24
0.150
9
0.62
0.0000
CIS80
0.27
0.116
5
0.29
0.0866
0.44
0.007
5
DOX80
0.32
0.064
0
0.39
0.0209
0.11
0.520
5
0.28
0.107
5
PRE50
0.04
0.819
3
0.20
0.2430
0.22
0.202
1
-0.02
0.921
9
0.21
0.2219
VIN80
-0.01
0.945
6
0.42
0.0099
0.12
0.501
5
-0.11
0.522
9
0.26
0.1373
0.31
0.061
5
GAM8
0
0.48
0.002
8
0.50
0.0020
0.15
0.391
7
0.03
0.852
6
0.59
0.0002
0.25
0.138
9
0.42
0.010
7
UV80
-0.07
0.678
7
0.17
0.3304
0.38
0.023
3
-0.15
0.389
0
0.13
0.4575
0.26
0.121
0
0.15
0.397
7
0.09
0.6139
CYA80
0.16
0.364
8
0.12
0.5040
-0.05
0.791
2
0.07
0.694
3
0.08
0.6483
0.47
0.003
6
0.34
0.041
0
0.14
0.4053
-0.16
0.351
1
VER80 -0.170.316
1
0.24
0.1675
0.24
0.161
1
-0.16
0.347
8
0.26
0.1270
0.39
0.017
8
0.53
0.000
9
0.31
0.0662
0.41
0.013
9
0.14
0.4097
Note: ID80 values were used, with the exception of the  ID50 values for prednisolon. Correlations
were calculated by using Spearman’s rank order regression analysis. The values shown are R-
values, with the corresponding p-values below; statistically significant correlations (p< 0.01) are
expressed in boldface. Abbreviations: ID80, inhibition dose 80% (prednisolon 50%); CLB,
chlorambucil; CDA, chlorodeoxyadenosine; FLU, fludarabine; CIS, cisplatin; DOX, doxorubicin;
PRE, prednisolon; VIN, vincristine; GAM, gamma irradiation; UV, ultraviolet irradiation; CYA,,
cyclosporine A; VER, verapamil.
54
It is conceivable that the CLL/PL patients are less drug sensitive than is the case with
the  typical  morphological  forms  of  CLL.  In  our  material  5/6  CLL/PL  cases  occurred  in  the  drug
resistance category (Table 7), which would suggest that the CLL/PL group seems to be more cross-
resistant than the typical morphological form of CLL.
Two P-glycoprotein-dependent drugs were analysed separately, namely doxorubicin
and vincristine. No correlation could be observed between these drugs (Figure 2). Three cases
(patient nos. 10, 19, 29) clustered differently from the others, indicating a cross-resistance.
Interestingly, none of the three belonged to the chemotherapy group, as could be assumed.
Figure 2. Relationships of vincristine and doxorubicin sensitivity of peripheral blood leukaemic
cells from 36 CLL patients. The comparison concerns ID80 values which were determined as
described in Methods section. The high values can be clustered in three different groups: i)
vincristine resistant alone, ii) doxorubicin resistant alone and iii) cross-resistant.
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4.2. Prognostic value of surface antigens in drug and irradiation
sensitivities (Study II)
In Study II, the prognostic value of surface antigens in drug and irradiation sensitivities were
analysed.
No statistically significant correlations were found between any surface antigen
expressions and drugs or irradiations sensitivities, when they were analysed by means of the
Spearman’s Rank Order Correlation test.
The expressions of CD80 divided the patients into two mutually exclusive groups as
regards the sensitivity to the purine analogues 2’-chlorodeoxyadenosine (p=0.0001, chi2-test, n=36)
and fludarabine (p=0.001, chi2-test, n=36). All resistant cases had a very low CD80 expression, as
indicated by the percentage of positive cells or by geometric mean fluorescence (Figure 3). In other
words, positive CD80 expression seems to sensitise a cell to purine analogues. A similar trend,
although not exclusive, was observed with chlorambucil (p=0.0017, chi2-test, n=36), doxorubicin
(p=0.1335, chi2-test, n=36) and prednisolon (p=0.51, chi2-test, n=36), but not with the other drugs
or the two types of irradiation tested.
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Figure 3. CD80 expression and the in vitro sensitivities of peripheral blood leukaemic cells from 36
CLL patients to fludarabine, chlorodeoxyadenosine, chlorambuil, doxorubicine and prednisolon.
ID80 values were used with the exception of prednisolon, for which ID50 was applied. CD80
expression was examined by determining the percentages of positive cells.
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4.3. Effect of immunoglobulin variable region mutation status on drug
and irradiation sensitivities (Study III)
The effect of IgHV mutation status on drug and irradiation sensitivities was analysed in Study III.
Out of the 24 patients, eight cases (33%) displayed mutated IgHV genes, whereas 16
(67%) cases were unmutated. The ID80 values were similarly distributed in both types of CLL; the
results are illustrated in Figure 4. The only statistically significant difference was seen with regard
to prednisolon, which had to be evaluated at the ID50 level, since ID80 was not achieved in all
cases even when a high dose of the drug was tested. UM-CLL cases were, on average, slightly more
sensitive than M-CLL cases (p=0.041).
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Figure 4. Sensitivity in vitro of peripheral blood leukaemic cells of 16 UM-CLL patients and 8 M-
CLL patients to nine drugs and two types of irradiation. The ID80 values (ID50 values for
prednisolon) are expressed in micro-mol/L, with the exception of gamma irradiation in Gy and UV
irradiation in J/m2. Medians and total ranges are illustrated. Open symbols = UM-CLL; closed
symbols = M-CLL.
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We also evaluated whether IgHV mutation status affects the variation of
drug/irradiation sensitivity in individual patients, so we assessed the distribution of heterogeneity of
intra-individual sensitivity in cases of M-CLL versus UM-CLL. To this end, we also determined the
ID20  values  and  adopted  the  ratio  of  ID80  per  ID20  as  a  measure  of  that  parameter.  The  results
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illustrated in Table 9 clearly demonstrate that there were no significant differences in intra-
individual heterogeneity of sensitivity to any of the toxic agents in these two groups of CLL.
Table 9. Heterogeneity of the sensitivity of UM-CLL and M-CLL cells to nine drugs and two types
of irradiation.
UM-CLL M-CLLDrugs and
irradiation types MEAN SD MEAN SD
Mann-Whitney U:
p
Chlorambucil 14.8 12.7 15.4 7.7 0.4260
Chlorodeoxyadenosine 40.7 44.9 24.7 23.5 0.3425
Fludarabine 19.4 25.7 9.3 3.3 0.5815
Cisplatinum 9.7 5.1 7.2 3.2 0.0662
Doxorubicin 19.9 20.7 27.9 40.5 0.7383
Prednisolone 72.15 244.27 93.52 123.15 0.0758
Vincristine 47.4 49.1 74.3 141.0 0.8065
Gamma-irradiation 31.8 31.9 30.4 19.2 0.7595
UV-irradiation 6.1 2.4 8.4 3.7 0.1417
Cyclosporin A 4.5 3.5 2.3 1.5 0.0662
Verapamil 16.4 17.7 15.1 12.7 0.3913
Note: Values represent ID80/ID20 ratios with the exception of prednisolon, for which the ratio
ID50/ID20 was determined.
4.4. Effect of Apoptosis associated genes to drug and irradiation
sensitivities (Study IV)
In Study IV the expression levels of apoptosis-associated genes were compared to drug and
irradiation sensitivities.
Untreated (23) and previously treated (9) groups were compared with the Mann-
Whitney U test. No statistically significant differences were observed in the expressions of
apoptosis-related genes between these groups; results are illustrated in Figure 5. Owing to very low
values, approaching the blank level, Bcl2l1 was excluded from the analyses. Rank-order
correlations were calculated between the expression levels of apoptosis-related genes and the ex
vivo ID80 values obtained for nine drugs and two types of irradiation (Table 10). No statistically
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significant positive correlations were demonstrated between chemo/radioresistance (large ID80
values) and the strength of the expression of anti-apoptotic genes (Bcl2, Bcl2a1 and Mcl1).
Similarly, the strength of the expression of pro-apoptotic genes (Bax, Myc and Dapk1) was not
associated with increased sensitivity (small ID80 values) to the agents tested. On the other hand,
several negative, albeit very weak, correlations between drug/irradiation resistance (large ID80
values) and the expression of anti-apoptotic genes were noted at the significance level of p < 0.05
(Table 10). These were between (i) Bcl2a1 and doxorubicin, (ii) Bcl2a1 and vincristine, (iii) Bcl2a1
and gamma irradiation, (iv) Mcl1 and gamma irradiation, (v) Mcl1 and cyclosporin A, (vi) Bcl2 and
cisplatin, and (vii) the Bcl2/Bax ratio and chlorodeoxyadenosine.
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Figure 5. Comparison of the expression at the mRNA level of apoptosis-related genes in 32 CLL
patients. Open symbols represent patients who had not received chemotherapy (n=23) and closed
symbols represent previously treated patients (n=9). Medians (squares), the 25th and 75th
percentiles (columns) and total range (whiskers) are illustrated.
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The ratios of Bcl2/Bax were  also  analysed  and  compared  to  the  drug  and  irradiation
sensitivities. There were no significant correlations between drug or irradiation sensitivities and
Bcl2/Bax ratios. Furthermore, the ratio did not vary at a statistically significant level between
untreated and treated groups.
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Table 10. Correlations between the expression of apoptosis-related genes and the ex vivo
cytotoxicity of nine drugs and two types of irradiation in vitro in cells from 32 patients with chronic
lymphocytic leukaemia.
Drug Apoptosis-associated gene expressions
Bax Bcl2l1 Bcl2a1 Dapk1 Myc Mcl1 Bcl2 Bcl2/Bax
CLB 0.000.979
0.30
0.100
0.01
0.952
-0.05
0.766
-0.03
0.879
-0.15
0.417
-0.33
0.069
-0.33
0.063
CDA 0.050.800
-0.06
0.760
-0.28
0.117
0.15
0.404
0.20
0.281
-0.14
0.460
-0.20
0.264
-0.36
0.045
FLU -0.080.654
-0.27
0.142
-0.08
0.659
-0.02
0.917
0.02
0.895
0.08
0.678
0.00
0.986
0.00
0.996
CIS -0.130.477
0.13
0.465
-0.22
0.217
-0.22
0.218
0.03
0.880
-0.24
0.194
-0.41
0.021
-0.31
0.083
DOX 0.110.548
-0.23
0.210
-0.42
0.019
0.17
0.371
0.28
0.120
-0.22
0.227
-0.21
0.261
-0.30
0.106
PRE 0.040.837
-0.09
0.621
-0.23
0.201
0.32
0.075
0.10
0.582
-0.12
0.508
0.12
0.501
0.00
0.994
VIN 0.020.921
-0.12
0.519
-0.41
0.018
0.24
0.194
0.16
0.394
-0.31
0.088
-0.30
0.094
-0.32
0.073
GAM 0.030.869
-0.08
0.680
-0.38
0.033
0.14
0.451
0.34
0.061
-0.38
0.033
-0.28
0.126
-0.34
0.058
UV 0.160.386
-0.33
0.069
-0.15
0.428
0.13
0.468
0.33
0.065
0.13
0.468
0.29
0.107
0.11
0.531
CYA -0.230.213
0.14
0.440
-0.21
0.241
0.16
0.385
-0.21
0.260
-0.40
0.022
-0.31
0.090
-0.09
0.621
VER 0.100.581
-0.23
0.197
-0.18
0.338
0.28
0.124
0.17
0.352
-0.01
0.954
0.17
0.347
0.07
0.712
Note: The values shown are R-values (above) with the corresponding p-values (below, in italics).
Correlations were calculated by using Spearman's Rank Order regression analysis. Statistically
significant correlations (p < 0.05) are indicated in boldface. Abbreviations: CLB, Chlorambucil;
CDA, Chlorodeoxyadenosine; FLU, Fludarabine; CIS, Cisplatin; DOX, Doxorubicin; PRE,
Prednisolon; VIN, Vincristine; GAM, Gamma irradiation; UV, Ultraviolet irradiation; CYA,
Cyclosporin A; VER, Verapamil.
Multiple regression analysis with a forward stepwise approach did not reveal any
statistically significant associations between the investigated genes and cytotoxicity ID80 values.
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DISCUSSION
5.1. Methodological considerations
Several methods have been used for cell counting in drug sensitivity studies. The Differential
Staining Cytotoxicity (DiSC) assay is a manual and labour-intensive method, while the 3-
(4,5.dimethyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a semiautomatic method. In
the current study, the cells’ viability was measured by the incorporation of radioactive 14C labelled
leucine to CLL cells. Leucine is one of the essential amino acids that a cell cannot produce by itself,
and measuring its radioactive labelled incorporation therefore reflects the strength of cell viability.
Leucine incorporation has been shown to correlate with living cells in many studies (Vilpo and
Vilpo 1996; Vilpo et al. 2000a; Vilpo et al. 2000b). In Study I we demonstrated good correlations
between tryptan blue excluding tests and the level of leucine incorporations. Koski has shown that a
decrease in leucine incorporation reflects apoptosis-like cell death as measured by DNA
fragmentation, annexin binding and propidium iodide permeability (Koski et al. 2000).
5.2. Multidrug resistance
The main interest for the treating physician is whether or not two drugs are equivalent in efficacy
and, therefore, non-cross-resistant. Cross-resistant drugs would not generally be given together, nor
would they be administered sequentially if the patient was clinically proven to be resistant to the
first one. The chlorodeoxyadenosine sensitivity among the present 36 CLL patients demonstrated a
close correlation with fludarabine, vincristine and gamma irradiation. The correlation between in
vitro responses to chlorodeoxyadenosine and fludarabine has also been demonstrated by others
(Bosanquet and Bell 1996; Bosanquet et al. 2009), and, furthermore, clinically relevant cross-
resistance has been reported (O'Brien et al. 1994). An entirely unexpected finding of the present
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study  was  the  disclosure  of  the  close  relationships  between  the  responses  to  drugs  with  very
different mechanisms of action, such as chlorodeoxyadenosine and vincristine as well as several
others. Although numerous mechanisms of drug resistance have been revealed, our results underline
the fact that very little is known about the complexity of the cellular mechanism of drug sensitivity
or resistance in a clinical context.
The present results clearly express a relationship between chemotherapy and drug
resistance ex vivo. The enhanced in vitro resistance was not necessarily against the same compound
as used in chemotherapy – this phenomenon has also been reported by others (Bosanquet and Bell
1996). For instance, six patients in the extreme/outlier group had been previously treated with
chlorambucil, but only one of the six was chlorambucil-resistant.
The multidrug resistant phenotype of CLL cells has been demonstrated in a number of
publications. While it is evident that the p-170 is expressed in a significant subset of CLL cases
(Sparrow et al. 1993; Burger et al. 1994; Matthews et al. 2006), no clear picture has emerged as to
whether their expression is associated with poor prognosis, an advanced stage or prior
chemotherapy (Friedenberg et al. 2004). The results of the current work were in accordance with
previously reported findings concerning the significance of MDR in CLL. No correlation could be
discovered between vincristine and doxorubicin, which are both p-170-dependent agents. Only
three patients (8.3%) were simultaneously resistant to both drugs, meaning that the p-170
mechanism was not relevant in rest of the cases. These findings are also in accordance with a
previous  study;  it  has  been  shown  that  CLL  cells  are  25  times  more  sensitive  to  vincristine  than
normal lymphocytes and the uptake and efflux in CLL versus normal lymphocytes are essentially
similar (Vilpo et al. 2000b).
The pleiotropic drug resistance observed in the present study and other investigations
strongly suggests that not only one but rather multiple resistance mechanisms are being induced by
chemotherapy (Bosanquet and Bell 1996; Bosanquet et al. 2009). According to our results, some
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drug resistance mechanism may still be undefined. The current study also provides new information
on putative drug combinations for clinical usage – all non-correlating drug combinations could be
putatively used.
The  minimal  residual  disease  (MRD)  status  has  been  shown  to  be  a  good  clinical
outcome predictor, since patients who achieved complete phenotypic remission as assessed by four-
or six-colour flow cytometry had a superior response duration and survival when compared with
patients who did not reach MRD (Varghese et al. 2010). Therefore, it is our opinion that ID80
values would reflect clinical outcome better than ID50 values, which have been used in many other
studies.
5.3. Prognostic factors of drug and irradiation resistance
Since the development of modern medicine, one of the most significant purposes for a physician has
been to provide the prognosis for the disease. There are many clinically relevant biochemical
prognostic factors in CLL, such as the expression of the CD38 surface antigen, the mutation status
of  the  IgHV  genes,  and  chromosomal  aberrations  (Van  Bockstaele  et  al.  2009).  In  CLL
chemotherapy there are only a few clinically relevant prognostic factors, namely chromosome 17p
deletion and mutation of p53 protein. If the p53 is mutated or chromosome 17p is deleted, the
prognosis for most of the drug therapy is poor (Zenz et al. 2008b).
The  surface  antigens  of  the  CLL  cells  are  routinely  defined  at  diagnosis.  We  went
through 32 surface antigens of 36 CLL patients and found no statistically significant correlations
between the expressions of surface antigens and drug or irradiation sensitivities. The expression of
the CD80 antigen predicts partly ex vivo cellular response to fludarabine and
chlorodeoxyadenosine. All of the cases with detectable expression of CD80 were sensitive to these
drugs when cells were tested in vitro. The same phenomenon, although not as clearly detectable,
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was observed with doxorubicin, chlorambucil and prednisolon. In most cases CD80 expression was
low.
The expression of the CD38 antigen is the most clinically used prognostic factor of the
surface antigens. The prognosis of the disease is poor, if the CD38 antigen expression of the CLL
cells is high (Krober et al. 2002; Hock et al. 2009; Van Bockstaele et al. 2009). In our material,
CD80 status did not correlate with CD38 expression. Expression of CD38 did not predict drug or
irradiation resistance.
CD80 – otherwise known as B7-1 – is a transmembrane glycoprotein expressed
mainly on activated antigen-presenting cells. It is also expressed on activated, but not on resting B
lymphocytes (Azuma et al. 1993). CD80 is an important costimulatory factor for the B cell receptor
(BCR) and in T cell stimulation (Collins et al. 2005). In most B cell lymphomas CD80 is expressed
at a low level, and in small lymphocytic leukaemia (SLL), which is a very similar disease to CLL, it
is  expressed at  a very low level or absent (Dorfman et  al.  1997).  It  has been demonstrated that in
CLL CD80 is expressed at a low level, as it is also in normal B lymphocytes, and the expression
level does not differ between stage I and stage IV cases (Dai et al. 2009). Our results are in
accordance with these findings.
The mutation status of the IgHV genes is the most powerful prognostic factor in CLL.
The only problem in terms of its clinical usage is that the testing is very labour-intensive. Prognosis
for the UM-CLL patient is clearly worse than for a M-CLL patient (Damle et al. 1999; Hamblin et
al. 1999), and treatment-free time from diagnosis is also clearly shorter in the UM-CLL group than
the M-CLL group (Wiestner et al. 2003). In our untreated CLL patients’ data, the sensitivities to
nine drugs and two types of irradiation were similar between the UM-CLL and M-CLL groups. In
others studies the results have been controversial; in in vitro studies,  UM-CLL patients have been
more sensitive than M-CLL patients to cytarabine and prednisolon (Aleskog et al. 2004), whereas
67
clinical studies have demonstrated that UM-CLL patients more often require therapy and respond
more poorly to chemotherapy, including fludarabine (Damle et al. 1999).
Apoptosis is very closely associated with CLL; one reason for the accumulation of
lymphocytes in CLL is the dysregulation of apoptosis (Danilov et al. 2006), and another reason is
the increased proliferation of lymphocytes (Messmer et al. 2005). Many of the chemotherapeutic
drugs exert their cell-killing effect through apoptosis (Burz et al. 2009). Mutation of the p53 protein
leads to drug resistance, but it is quite rare in CLL and thus cannot explain drug resistance in most
cases (Zenz et al. 2008a). The Bcl2 protein family, and especially the Bcl2 protein, is the most
investigated apoptosis-associated protein (Buggins and Pepper 2010).
In most studies overexpression of the Bcl2 protein has been connected to chlorambucil
resistance (Pepper et al. 1997; Pepper et al. 1998; Pepper et al. 1999; Thomas et al. 2000; Pepper et
al. 2001), but also negative results, as ours, have been found (Johnston et al. 1997; Bosanquet et al.
2002). Low expression of the Bax protein has been connected to, among other treatments,
chlorambucil and fludarabine in CLL (Bosanquet et al. 2002; Pepper et al. 2008), whereas negative
results have been found concerning, for example, fludarabine and chlorambucil (Johnston et al.
1997; Bosanquet et al. 2002). A high expression of Mcl1 is associated with rituximab and
fludarabine resistance, and it has also been correlated with the stage of disease (Bannerji et al. 2003;
Pepper  et  al.  2008).  Low  Mcl1  expression  has  been  connected  to  complete  clinical  treatment
responses in CLL (Kitada et al. 1998; Saxena et al. 2004), although negative results have been
published in this regard as well (Grever et al. 2007).
The ratio of anti- and pro-apoptotic proteins, such as the Bcl2/Bax or Mcl1/Bax ratio,
is believed to be more important than the expression level of individual proteins. A high ratio of
Bcl2/Bax indicated the coincidence of a high expression of Bcl2 and a low expression of Bax. In
most of studies, a high Bcl2/Bax ratio has been connected to chlorambucil and fludarabine
resistance (Pepper et al. 2001), although negative results have also been observed with fludarabine,
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chlorambucil, chlorodeoxyadenosine, cladribine and prednisolon (Johnston et al. 1997; Bosanquet
et al. 2002).
The results of previous studies have been conflicted. In our current data we did not
find any statistically significant and biologically relevant correlations between the expressions of
apoptosis-associated genes and drug or irradiation sensitivities. Seven negative correlations between
the expressions of the anti-apoptotic genes and drug resistance were observed, but these were very
weak and remained without a biologically relevant explanation. Our results are not directly
comparable with other studies, because others have examined the levels of apoptosis-associated
proteins whereas we studied the expression levels of apoptosis-associated genes.
Gene expression in quiescent CLL cells is regulated at different levels: i) regulation of
RNA transcription, ii) regulation of mRNA stability and iii) regulation of mRNA translation. In
CLL the dysregulation of mRNA translation and decay has been investigated from at least two
different perspectives. MicroRNAs (miRNA) are a class of small non-coding RNAs regulating
mRNA translation and decay. Bcl2 mRNA is negatively regulated by two miRNAs, miR-15a and
miR-16-1. These two microRNAs are located in the chromosome 13q region, and they are deleted
in major of cases in CLL (Nicoloso et al. 2007). Furthermore, microRNAs have been linked to the
progression and outcome of CLL (Calin et al. 2007). Nucleolin is a cytosolic protein which
stabilises Bcl2 mRNA  and  thus  leads  to  elevated  translation  of  the  Bcl2  protein.  The  level  of
nucleolin has been shown to be increased in CLL (Otake et al. 2007).
These regulation mechanisms may explain the different results between the current
study and most other reports. Moreover, only the regulation mechanisms of Bcl2 are known, and it
could be expected that other genes also have some kind of as yet undetermined regulation
mechanisms, which could explain the differences between the expression levels of genes and
protein.
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5.4. Limitations of the study and future directions
In  the  present  study  series,  the  number  of  patients  investigated  was  quite  small,  and  the  results
included data from both treated and untreated patients. On the other hand, this enables the
comparison between untreated and treated patients. Multiple comparison tests have an internal
tendency to reveal non-existing correlations. In our Study I, we used small P-values of <0.01 as an
indicator for significant finding, and even when multiplied by 10 (corresponding to 10 comparisons
in each family), only one of the P-values became higher than 0.05.
The combination of two or three drugs is currently the most common therapy in CLL.
Combined chemotherapies are mostly based on fludarabine, which was included in our
investigation. Fludarabine is commonly combined with cyclophosphamide (Catovsky et al. 2007)
and in recent years also with biological agents such as Rituximab (Tam et al. 2008).
Cyclophosphamide or biological drugs were not included in the current study series. Biological
agents will play a more important role in future treatments, which is why they should be included in
future investigations.
The  expression  of  the  CD80 surface  antigen  seems to  predict  the  sensitivity  of  CLL
cells to fludarabine and chlorodeoxyadenosine and, to a degree, also to doxorubicin, chlorambucil
and prednisolon. Flow cytometry analysis is used in the diagnosis of CLL, but expressions of CD80
are not determined routinely. It would be easy to include it in future as a diagnostic tests.
MicroRNAs and their connections to different diseases have been extensively
investigated in recent years. In CLL several microRNAs have been found to be connected to the
pathogenesis of the disease – these include miR-15, miR-16, miR-29c and miR223. The
significance of these microRNAs for drug resistance has not been investigated to date, and this
would be an interesting area to explore.
The present sensitivity results were obtained from an in vitro analysis and, as such, do
not necessarily directly reflect clinical outcome, although good correlations between in vitro assays
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and clinical outcome have been demonstrated (Bosanquet et al. 1999a; Bosanquet et al. 1999b). For
this reason, we collected data on the later clinical responses for this patient group. Only three cases
from the outlier and extreme group had received the same drug in subsequent chemotherapy to
which they had demonstrated in vitro resistance. All three patients had only a partial response
against these drugs, reflecting directional connections between in vitro and clinical responses.
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SUMMARY AND CONCLUSIONS
In the present study series, peripheral blood leukaemic cells of 36 CLL patients were subjected (?)
to nine drugs and two types of irradiation. For the purposes of determining the sensitivity of the
CLL cells to the investigated agents, ID80 values were measured. Cross-resistance as well as the
impact of i) previous treatment, ii) surface antigens, iii) IgHV gene mutation status and iv) the
expression of apoptosis-associated genes on drug resistance were analysed.
I Drug or irradiation resistance is more common after chemotherapy, but in most of
cases the resistance was not to the same drugs as used in chemotherapy. Cross-
resistance was noted between the same drug group agents fludarabine and
chlorodeoxyadenosine, but also between very differently acting drugs such as
chlorodeoxyadenosine and vincristine. The commonly accepted P-glycoprotein-
dependent drugs, doxorubicin and vincristine, were not correlated, indicating that
there must be multiple resistance mechanisms rather than one mechanism.
II The expression of the CD80 antigen seems to predict fludarabine and
chlorodeoxyadenosine sensitivities in CLL patients. All of our study cases with a
detectable expression of this antigen were sensitive when tested in vitro.
III The mutation status of IgHV genes did not predict the in vitro sensitivities of the
investigated drugs or irradiations in the untreated CLL patient group.
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IV Expressions of apoptosis-associated genes (anti-apoptotic: Bcl2, Mcl1, Bcl2a1, Bcl2l1
and pro-apoptotic: Bax, Myc, Dapk1) were not determinants of the investigated drug
or irradiation sensitivities in CLL.
Drug resistance  seems to  be  more  common after  chemotherapy.  Previous  treatments
may cause drug resistance against other drugs besides the ones used in the therapy. Detectable
expression of the CD80 surface antigen seems to predict fludarabine and chlorodeoxyadenosine
sensitivity in CLL patients. The mutation status of IgHV genes or expressions of apoptosis-
associated genes are not determinants of drug or irradiation sensitivity in CLL.
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Abstract
Extensive research into mechanisms of cytotoxic drug and irradiation resistance have produced few clinically encouraging results. In this
report, we apply correlation analyses to drug and irradiation response results from a cohort of 36 classical B chronic lymphocyte leukemia
(CLL) patients. Nine drugs and two types of irradiation were selected according to their usefulness in CLL therapy or on the basis of
their otherwise interesting mechanisms of action. Part of the results concerning individual drugs have been previously published, but new
correlation analyses are presented in this paper. Altogether 2376 duplicate cultures were performed in order to determine ID80 values, i.e.
doses causing an 80% inhibition in 4-day cultures when leucine incorporation was used as an indicator of cells vitality. Non-parametric
Spearman’s rank order correlation confirmed a tight relationship between 2-chlorodeoxyadenosine and fludarabine, as expected. Surpris-
ingly, correlation between two P-glycoprotein-dependent drugs, vincristine and doxorubicin, was not demonstrable. A number of entirely
unexpected correlations were identified between drugs with very different mechanisms of action: (i) chlorambucil and -irradiation; (ii)
2-chlorodeoxyadenosine and vincristine; (iii) 2-chlorodeoxyadenosine and -irradiation; (iv) fludarabine and cis-platin; (v) doxorubicine
and -irradiation; (vi) prednisolone and cyclosporin A; (vii) vincristine and verapamil. Our findings emphasize: (i) the usefulness of fresh
tumor cells instead of cell lines in cytotoxicity studies; (ii) the great variation in cytotoxicity in individual patients, i.e. tumor cell hetero-
geneity, as well as patient heterogeneity; and (iii) an entirely unexpected finding that there were tight relationships in drug and irradiation
responses between substances supposed to act with very different mechanisms.
© 2002 Elsevier Science Ltd. All rights reserved.
1. Introduction
In cancer chemotherapy the major obstacle is drug re-
sistance (for a review, see [1]). Since, the introduction
and development of drug-resistant cell lines, mechanisms
of drug resistance have been extensively investigated, but
cell line models used to investigate these mechanisms may
not directly pertain to the clinical resistance [2]. Many
drug resistance mechanisms have been revealed in chronic
lymphocytic leukemia (CLL). These include multidrug re-
sistance associated with P-glycoprotein and several other
mechanisms like multidrug resistance-associated protein,
non-P-glycoprotein-mediated transport mechanisms, gluta-
tione S-transferase and glutathione levels, topoisomerases,
metallothioneins, p53 gene mutation, and drug-specific
resistance mechanisms (see Bosanquet and Bell [2]).
∗ Corresponding author. Tel.: +358-3-247-5290; fax: +358-3-247-4048.
E-mail address: juhani.vilpo@tays.fi (J. Vilpo).
We have recently demonstrated with a cohort of 36 clas-
sical CLL patients that the ex vivo sensitivity of CLL cells
to various chemotherapeutic substances is highly variable.
This concerns both inter- and intra-individual variation,
which has been demonstrated with: (i) -irradiation [3];
(ii) UV-irradiation [4]; (iii) cyclosporin A [5]; (iv) cal-
cium antagonists alone and together with several classic
antileukemia drugs [6]; (v) vincristine [7,8]; (vi) 2-chloro-
deoxyadenosine and fludarabine [9]; as well as with (viii)
prednisolone, doxorubicin, cis-platin and chlorambucil [10].
It is likely that the improvement of clinical results can be
achieved by individualizing the anticancer therapy. This, on
the other hand, means that more information of the relation-
ship about the action of various therapy modalities should
be available. For instance, previous correlation analyses
by others [11] and by us [9] have demonstrated that the
sensitivity spectra of 2-chlorodeoxyadenosine and fludara
are very similar. In this paper, we report further correlation
analyses concerning the same data and cohort of 36 CLL
patients [3–10]. Unexpectedly, significant statistical correla-
0145-2126/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
PII: S0 1 4 5 -2126 (02 )00050 -4
1036 I. Kivekäs et al. / Leukemia Research 26 (2002) 1035–1041
tions were noted in drug and irradiation responses between
substances considered to act in very different ways.
2. Materials and methods
2.1. Patients and samples
Clinical specimens were obtained after informed con-
sent from 36 consecutive CLL patients referred to the CLL
out-patient clinic at Tampere University Hospital (Finland).
Diagnosis and staging were based on standard clinical, mor-
phological and immunophenotyping criteria. All patients had
a CD19+/CD23+/CD5+ immunophenotype (the cohort has
been reanalyzed in 2000) and mature CLL, CLL/mix or
CLL/PL morphology [12]. Most patients had chromosomal
aberrations but none indicated chronic lymphoid leukemias
other than typical CLL [10].
Peripheral blood mononuclear cells were isolated from
heparinized (Noparin, Novo Nordik, Dagsvaerd, Denmark)
blood samples by centrifugation over a Lymphoprep layer
(Nycomed, Oslo, Norway) at a density of 1.077 g/ml. The
cells were washed twice with phosphate-buffered saline
(PBS, pH 7.4) and once with medium consisting of RPMI
1640 (20 mM Hepes, ICN Biochemicals, Costa Mesa, CA),
10% heat-inactivated fetal calf serum (Gibco BRL, Paisley,
Scotland), 2 mM l-glutamine (Gibco BRL) and antibiotics
(penicillin 50 U/ml, streptomycin 50g/ml from Gibco
BRL). Cell counting was performed by using Technicon H1,
H2 or H3 analyzers (Bayer Diagnostica). Density gradient
centrifugation yields—without other purification steps—
were good (range 29–92%; mean 61.7%; S.D. 16.2%, n =
36). This information is necessary for interpretation of the
results [13]. The proportion of monocytes plus polyclonal
T- and B-lymphocytes was 1–13%, indicating that 87–99%
of the isolated cells represented the leukemic population
(reanalyzed in 2000).
Immunophenotyping was performed by flow cytometry
(FACSCalibur, Becton Dickinson immunocytometry sys-
tems, CA) using commercial mouse monoclonal antibodies
and, respective immunoglobulin isotype controls.
2.2. Chemo- and radio-sensitivity in vitro
2.2.1. Drugs and irradiation
Following drugs and types of irradiation were used.
Chlorambucil (Sigma, St. Louis, MO); 2-chloro-2′-deoxy-
adenosine (Sigma); cyclosporine (cyclosporin A, Sandoz
Pharmaceutical Co., Basle, Switzerland); cis-platinum(II)
diammine-dichloride (cis-platin, Sigma); Doxorubicin
hydrochloride (adriamycin 2 mg/ml, Pharmacia, Upp-
sala, Sweden); 2-fluoroadenine-9--d-arabinofuranoside
(fludarabine, Sigma); prednisolone natrium succinate;
di-adreson-F (prednisolone, N.V. Organon, Oss, The Nether-
lands); verapamil (verpamil 2.5 mg/ml, Orion Ltd., Espoo,
Finland); -irradiation 0.007 Gy/s (137Cs source; Molsgaard
Medical, Denmark); UV-irradiation 1 J/m2/s (UV Unit;
Gelman Sciences, Ann Arbor, MI).
2.2.2. Cytotoxicity assay
The methodology has been described in more detail in
the original papers [3–10]. In short, the cytotoxic effects of
nine drugs and two types of irradiation against peripheral
blood lymphocytes from 36 CLL patients were assessed
using 4-day cultures by adding five different concentrations
of test drugs to the cultures in 96-well microplates. Alter-
natively, the cells were initially irradiated by five different
doses of ionizing and UV-irradiation. The 200,000 cells per
well were seeded in a volume of 100l (2 × 106 cells per
ml). The test substances were selected according to their
usefulness in CLL therapy on one hand and on the basis
of their individual mechanisms of action on the other. Ef-
fects were monitored by assessing protein synthesis using
[14C]-leucine incorporation. The cells were cultured for
4 days. [U-14C]-leucine (specific activity 1.3 mCi/mmole,
0.5Ci/ml) was added for the final 24 h of culture. Af-
ter incubation, the proteins were precipitated with 0.2 M
perchloric acid and collected on glass fiber filters using
a multiple cell harvester (LKB Wallac 1295–001, Turku,
Finland). The radioactivity incorporated was measured by a
liquid scintillation counter (Wallac 1410). The ID80 values
were calculated from dose-response curves using duplicate
or triplicate assays with 5 drug or irradiation doses.
2.3. Statistical treatment
Correlations were calculated using Spearman’s rank order
correlation test. The proportion comparison was performed
by χ2-test. Statistical analyses were performed using a sta-
tistical package: STATISTICA for Windows (ver Win 5.1D,
1996 StatSoft Inc., Tulsa, OK).
3. Results
We have previously demonstrated a good correlation be-
tween the number of living cells and leucine incorporation
in 4-day cultures ex vivo by using cyclosporin A, verapamil
and vincristine [5,6,8,14]. Here, a very good correlation be-
tween cell numbers and leucine incorporation in 4-day ex
vivo cultures is demonstrated with six other drugs and two
types of irradiation (Fig. 1).
The results of the cytotoxicity testing of nine drugs
and two kinds of irradiation against the peripheral blood
leukemic cells of 36 CLL patients are illustrated in Fig. 2.
These results are based on 2376 duplicate cultures. From the
nine drugs tested, 2-chlorodeoxyadenosine and vincristine
induced an 80% median inhibition in leucine incorporation
by lowest drug concentrations. Correspondingly, the drugs
requiring the highest concentrations for a similar effect
were verapamil and cis-platin. Cyclosporin A demonstrated
the lowest variation and prednisolone the highest variation
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Fig. 1. Correlation between leucine incorporation (dpm per culture well;
abscissa) and living cell concentration (trypan blue-excluding cells per
ml; ordinate) in ex vivo cultures of randomly chosen example patients.
In order to facilitate the comparison, all cases were scaled to a common
(% of maximum) level. The upper panel demonstrates the progression of
cell death during the culture period. The best correlation was observed
on day 4 of culture. The lines represent the least-squares regression by
Pearson’s method. A corresponding correlation coefficient is given above
each panel. Despite good linear correlation in all cases, sometimes leucine
incorporation was more sensitive than the living cell counts (eg. 2-CDA,
fludarabine and -irradiation).
Fig. 2. Sensitivity in vitro of peripheral blood leukemia cells of 36 CLL patients to nine drugs and two types of irradiation. The abbreviations are: (CLB)
chlorambucil; (CDA) 2-chlorodeoxyadenosine; (FLU) fludarabine; (CIS) cis-platin; (DOX) doxorubicine; (PRE) prednisolone; (VIN) vincristine; (GAM)
-irradiation; (UV) UV-irradiation; (CYA) cyclosporin A; (VER) verapamil. Median values, ranges, outliers and extremes are illustrated according to the
statistics given on the right side of the figure. The ranges of outliers and extremes are illustrated in the classic box and whisker plot where the upper
box value is the 75%, the lower box value is the 25%. The outlier coefficient is equal to 1.5 and the extreme coefficient equal to 3. The ID80 values
are expressed in M, with the exception of -irradiation in Gy, and UV-irradiation in J/m2. The patients having outlying or extreme values are further
characterized in Table 2.
among these toxic substances. Furthermore, the ID80-values
for prednisolone could not be determined for all patients.
Hence, we used ID50-values instead.
The extreme and outlier values are separately illus-
trated (Fig. 2). This was our statistical approach to de-
termine relative cellular drug resistance. Individual cases
are discussed in Table 2. Among the nine patients hav-
ing received chemotherapy six had one or more outlying
and extreme ID80 values. In contrast, only eight patients
not having received chemotherapy belonged to the out-
lier/extreme group. This result indicates that the ratio of
resistant:sensitive cases in the chemotherapy group was 4.8
times larger as compared with the previously and currently
untreated patients (P = 0.0484, χ2-test, n = 36).
There was a poor concordance between previous or on-
going drug therapy and the in vitro drug-resistance. In three
cases, the patient had received the same drug against which
he or she demonstrated drug resistance. These were patient
8 showing chlorambucil and doxorubicin resistance and pa-
tient 24 showing doxorubicine resistance.
In addition to the inter-individual variation in the re-
sponses to toxic substances, there was a strong intra-indivi-
dual variation, i.e. tumor cell heterogeneity. In many
instances, the dose-response curves of individual patients
spun over a 100-fold concentration difference [3–10]. The
inter-relationships of different toxic agents were analyzed by
using the non-parametric Spearman’s rank order correlation
analysis. As illustrated in Table 1, there was strong evidence
(P < 0.01) about a statistical relationship of the sensitivities
of CLL cells to: (i) chlorambucil and -irradiation
(P = 0.0028); (ii) 2-chlorodeoxyadenosine and fludara-
bine (P < 0.0001); (iii) 2-chlorodeoxyadenosine and vin-
cristine (P = 0.0099); (iv) 2-chlorodeoxyadenosine and
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Fig. 3. Relationships of drug and irradiation sensitivities in three CLL
patient groups. The drug/irradiation pairs were selected according to their
best correlation as assessed by Spearman’s rank order correlation test
(P < 0.01 in any of the three patient groups illustrated): all patients
n = 36, non-treated n = 27, treated n = 9; the abbreviations are similar
to those used in Fig. 2.
-irradiation (P = 0.0020); (v) fludarabine and cis-platin
(P = 0.0075); (vi) doxorubicine and -irradiation (P =
0.0002); (vii) prednisolone and cyclosporin A (P =
0.0036); and (viii) vincristine and verapamil (P = 0.0009).
The number of statistically significant correlations was much
Table 2
Patients having extreme and outlier ID80 values in cytotoxicity testing
Patient # (FAB type) Drugsa ID80 (M or J/m2) Previous treatmentb
2 (CLL) Fludarabine (O) –c 9.5 LP
8 (CLL/PL) Chlorambucil (E) + 80.4 LP, 6 × COP, 7 × CHOP
2-Chlorodeoxyadenosine (E) – 35
Fludarabine (E) – 22
Doxorubicin (E) + 7.0
UV-irradiation (E) – 92
10 (CLL) Chlorambucil (E) – 165 None
2-Chlorodeoxyadenosine (E) – 10
Fludarabine (E) – 34
Doxorubicin (E) – 8.5
11 (CLL) UV-irradiation (E) – 92 L
14 (CLL/PL) 2-Chlorodeoxyadenosine (E) – 10 LP, 7 × COP, 10 × CHOP
Fludarabine (E) – 30
15 (CLL) Doxorubicin (O) – 2.6 None
18 (CLL, mix) 2-Chlorodeoxyadenosine (E) – 5.1 None
Fludarabine (E) – 14
19 (CLL/PL) Doxorubicin (E) – 5.3 None
Cyclosporin A( O) – 7.5
20 (CLL/PL) 2-Chlorodeoxyadenosine (E) – 7.1 None
Fludarabine (E) – 19
21 (CLL, mix) Doxorubicin (O) – 3.1 None
22 (CLL/PL) Doxorubicin (E) – 10 None
24 (CLL, mix) 2-Chlorodeoxyadenosine (E) – 6.0 4 × CHOP, LP
Fludarabine (O) – 7.0
Doxorubicin (E) + 5.0
Cyclosporin A (O) – 4.4
29 (CLL) Doxorubicin (E) – 10 None
31 (CLL) 2-Chlorodeoxyadenosine (O) – 3.0 LP
a (E) extreme and (O) outlier (as shown in Fig. 1).
b L, leukeran (chlorambucil); P, predniso(lo)ne; CH(O)P, cyclophosphamide-(hydroxydaunorubicin (doxomycin)-oncovine(vincristine)-prednisolone.
c (–) Not given previously; (+) previously given.
Fig. 4. Relationship of vincristine and doxorubicine sensitivity of periph-
eral blood leukemic cells from 36 CLL patients. The comparison con-
cerns ID80 values which were determined as described in Section 2. The
high values clustered in three different groups: (i) vincristine resistence
alone, (ii) doxorubicine resistance alone, and (iii) double-resistance; the
numbers of the most resistant patients are illustrated.
larger than that expected by a chance alone. Fig. 3 further-
more illustrates that these correlations did not remarkably
change if the nine treated patients were excluded. However,
the correlations of treated patients (Fig. 3) were different:
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(i) 5/9 demonstrated a stronger correlation, (ii) 1/9 a similar,
and (iii) 3/9 less stringent correlation than in the total or
non-treated patient groups.
It is conceivable that the CLL/PL patients are less drug-
sensitive than the typical morphological forms of CLL. This
was the case and 5/6 CLL/PL cases occurred to belong to
the drug resistant category (cf. Table 2). Accordingly, the
omission of CLL/PL cases from Table 1 would decrease the
number of significant correlations from 8 to 5.
We also wanted to analyze whether a correlation exists be-
tween two P-glycoprotein-dependent drugs vincristine and
doxorubicine (cf Table 1). No such correlation could be
observed between the ID80-values of vincristine and dox-
orubicine (Fig. 4). Three cases (patient nos. 19, 29 and
30) clustered very differently from the others indicating a
cross-resistance. Interestingly, none of the three belonged to
the chemotherapy group.
4. Discussion
Several methods have been used in order to assess the
chemosensitivity of CLL leukemia cells ex vivo. These in-
clude Differential Staining Cytotoxicity (DiSC) assay [2]
and 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay [15]. The former is a manual [2] and evidently
a labor-intensive technique while the latter is a semiauto-
matic method [16] like that one used in the present investi-
gation. All these assays use different end-points. Hence, the
validation of the laboratory method is important. We have
previously demonstrated that there are very good correla-
tions between the numbers of living cells and leucine in-
corporation in 4-day cultures although very different toxic
drugs, such as calcium channel antagonists, vincristine and
cyclosporine were investigated [5,6,8]. Here, we extend this
laboratory validation to concern all other toxic substances
used in this investigation.
Extensive research into mechanisms of cytotoxic drug
and irradiation resistance have produced few clinically en-
couraging results. This can partially be explained by an in
vivo-induction of post-treatment pleiotropic resistance, the
phenomenon, which has carefully been investigated with
CLL cells: the conclusion was that the pleiotropic resistance
observed in fresh CLL cells is most likely caused by the com-
plex interplay of a number of resistance mechanisms, some
of which may yet be undefined [2]. Similarly, the present in-
vestigation clearly revealed a relationship between previous
or ongoing chemotherapy and drug resistance ex vivo. Sur-
prisingly, the enhanced in vitro resistance was not necessar-
ily against the same compound, e.g. chlorambucil, which had
been used in clinical chemotherapy. This is in accordance
with the previous results, according to which, for exam-
ple treating patients with anthracyclines (MDR-associated
drugs) induced more ex vivo resistance to steroids and plat-
inums while treating with cyclophosphamide induced resis-
tance to all the MDR drugs except vincristine [2].
Begleiter et al. have previously demonstrated the cross
sensitivity of CLL cells to 2-chlorodeoxyadenosine and
fludara [11]. The assay strategy used in the present series
of investigations has confirmed this finding, although
cross-resistance cannot be assumed in all CLL patients [9].
An entirely unexpected finding of the present work was the
disclosure of tight relationships between responses to drugs
with very different mechanisms of action (cf. Table 1), such
as 2-chlorodeoxyadenosine and vincristine and several oth-
ers. This strongly emphasizes the fact that finally very little
is known about the complexity of cellular mechanisms of
drug sensitivity or resistance in a clinical context.
The current material represents a normal cohort of CLL
patients referred to a university hospital. It is important to
recognize special characteristics of minor groups, such as
cases with CLL/PL morphology and pre-treated cases. These
groups may have reduced drug sensitivity, as also demon-
strated with this patient cohort.
The multidrug-resistant phenotype of CLL cells has been
demonstrated in a number of publications. P-glycoprotein is
frequently expressed at diagnosis [17] and functional drug
efflux [18–20] has been demonstrated in vitro. Furthermore,
it has been shown that CLL cells are resistant to anthracy-
clines [21]. The results of the recent and current work from
our laboratory point to an entirely different conclusion about
the significance of MDR in CLL. We have recently shown
that, despite a 25-fold sensitivity of CLL cells to vincristine
[7], the uptake and efflux in CLL versus normal lympho-
cytes are essentially similar [8]. This excludes any signifi-
cant role for MDR in the tremendous in vitro sensitivity of
CLL cells to vincristine. Furthermore, no correlation could
be revealed between vincristine and anthracycline sensitivi-
ties in the present investigation. Only three patients (8.3%)
were simultaneously resistant to both drugs meaning that
MDR mechanisms were not detectable in the rest of the
cases. Interestingly, the three cross-resistant cases belonged
to the non-chemotherapy group and, hence, presented a si-
multaneous de novo resistance to these two drugs.
We have recently demonstrated that calcium channel
antagonists verapamil and nifedipine as well as the im-
munosuppressive drug cyclosporin A are toxic against CLL
cells in vitro [5,6]. In addition, verapamil and nifedipine po-
tentiated the action of non-P-glycopotein-dependent drugs
[5,6]. With an exception of verapamil versus vincristine, the
present investigation did not reveal correlation of either of
these two types of compounds with any other modalities of
in vitro treatment used in the present work. This may mean
that the mechanism of action of these two drugs are very
different from the others and deserve more scrutiny towards
clinical chemotherapy in CLL. On the other hand, the tight
correlation, even between very different drugs, may indi-
cate similarities in the mechanisms of action. For instance,
2-chlorodeoxyadenosine sensitivity among 36 CLL patients
correlated tightly, in addition to fludarabine, vincristine as
well as to ionizing radiation. It is very likely that this kind
of observational investigation, although enabling the confir-
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mation of the statistical relationship, can never confirm the
biological inter-relationship.
Multiple comparison procedures have an internal ten-
dency to reveal non-existing correlations. The comparisons
performed in this work represent 10 families of related tests,
each of the toxic substances against all others. There are
very few possibilities to accurately determine the P-values
in this kind of situation. One very robust and conservative
approach may be based on the Bonferroni-type inequality,
generally used with variance analysis. If each P-values in
Table 1 were multiplied by 10 (corresponding to 10 compar-
isons inside each family) only one of the P-values (CIS80
versus FLU80) would become larger than 0.05, the others
still remaining 0.036 or below.
Even without accurate knowledge of the mechanisms, this
new information about the toxic substances may be rele-
vant in the clinical context. However, this remains to be
investigated. If this similarity concerns an upstream (puta-
tive) component of the death signal, a cross-resistance may
be expected. On the other hand, if the similarity is distal in
the death signal pathway, the cancer cell damage may be
additive or even synergistic. This is a novel area of cancer
research and deserves further investigation.
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Abstract
We investigated the correlation between expression of 31 surface membrane antigens and chemosensitivity of peripheral blood mono-
nuclear cells from 36 patients with CLL. The sensitivity of CLL cells to nine drugs (2′-chlorodeoxyadenosine, cisplatin, chlorambucil,
cyclosporin A, doxorubicin, fludarabine, prednisolone, verapamil and vincristine) and two types of irradiation (gamma and UV-irradiation)
was determined from dose-response curves of 4-day cultures ex vivo. The results indicated that the CLL cases responding to purine analogs
(2′-chlorodeoxyadenosine and fludarabine) can be identified according to CD80 expression: all resistant cases had low or negative CD80
expression. No other correlations were revealed. CD80 may be a surrogate chemosensitivity marker for purine analogs. © 2002 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
In cancer chemotherapy a major obstacle is drug resis-
tance. CLL is not an exception. Chemosensitivity assays may
bring specific guidance to avoid ineffective compounds and
to potentially direct chemotherapy towards more success-
ful treatment at each point of disease progression [1]. Cell
surface markers are crucial for current diagnostics of CLL.
Some markers, such as CD25, CD38 and serum-soluble
CD23 are associated with a more adverse clinical course
of CLL (for a review, see [2]). Here we report that surface
membrane antigen expression was of low value in predicting
the ex vivo irradiation or chemotherapy response. The main
exception was CD80 expression, predicting the response of
CLL cells to purine analogs.
2. Materials and methods
2.1. Patients and samples
Clinical specimens were obtained after informed consent
from 36 consecutive CLL patients with a CD19+/CD5+/
Abbreviations: CD, cluster of differentiation; CLL, chronic lymphocytic
leukemia
∗ Corresponding author. Tel.: +358-3-247-5290; fax: +358-3-247-4048.
E-mail address: juhani.vilpo@tays.fi (J. Vilpo).
CD23+ immunophenotype and mature CLL, CLL/mix or
CLL/PL morphology (FAB classification). Most patients had
chromosomal aberrations but none indicating chronic lym-
phoid leukemias other than typical CLL [3].
Peripheral blood mononuclear cells were isolated from
heparinized blood samples by centrifugation over a Lympho-
prep layer as described [3]. Density gradient centrifugation
yields—without other purification steps—were good (range
29–92%; mean, 61.7%; S.D., 16.2%; n = 36). The propor-
tion of monocytes plus polyclonal T- and B-lymphocytes
was 1–13%, indicating that 87–99% of the isolated cells
represented the leukemic population.
2.2. Immunophenotyping
Immunophenotyping was performed by flow cytom-
etry (FACSCalibur, Becton Dickinson Immunocytome-
try systems, San Jose, CA) using commercial mouse
monoclonal antibodies and respective immunoglobulin
isotype controls. The antibodies used are illustrated in
Table 1.
Staining was performed according to the suppliers’
instructions. For cell surface immunoglobulin staining, the
cells were first incubated in PBS (pH 7.4) at 37 ◦C for
30 min to remove heterophilic antibodies. The buffers used
in all the steps did not contain serum.
0145-2126/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
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Table 1
Monoclonal antibodies used
Antigen (source)a Label Isotype
control
Clone
CD2 (B) FITC 2a Leu-5b
CD4/CD8 (B) FITC/PE 1/2a Leu-3a/leu-2a
CD20 (B) FITC 1 Leu16
CD45RA (B) FITC 1 Leu-18
CD45RO (B) PE 2a Leu-45RO
CD122 (B) PE 1 Anti-IL-2R-p75
CD19 (B) PE 1 SJ25C1
CD5 (B) FITC 2a Leu-1
CD23 (B) PE 1 Leu-20
FMC7 (I) FITC  FMC7
CD22 (B) FITC 2b Leu-14
CD34 (B) PE 1 8G12
CD38 (B) PE 1 Leu-17
CD10 (B) FITC 2a Anti-CALLA
CD124 (I) PE 1 S4-56C9
CD126 (I) PE 1 M91
CD11c (D) FITC 1 KB90
CD14 (D) FITC 2a TUK4
CD21 (D) FITC 1 1F8
CD79b (D) FITC 1 SN8
mIgG (P) FITC 1 G18-145
mIgD (P) FITC 2a IA6-2
mIgM (P) PE 1 G20-127
CD95 (P) FITC 1 DX2
CD40 (P) FITC 1 5C3
CD27 (P) FITC 1 M-T271
CD130 (P) PE 1 VC041
CD25 (B) FITC 1 Anti-IL-2R
CD154 (B) PE 1 Anti-gp39
CD80 (B) PE 1 Anti-B7
CD45/CD14 (B) FITC/PE 1/2b Anti-Hle-1/leu-3M
/ (B) FITC/PE 1/1 TB28-2/1-155-2
a B: Becton Dickinson; D: Dako; I: Immunotech; P: Pharmingen.
For more accurate description of antigen proteins, see, e.g. http://www.
ncbi.nlm.nih.gov/PROW.
The forward scatter channel was checked prior every
analysis using unlabeled calibration particles (SPHERO
Calibration Particles, blank 6.5–8m, Pharmingen). The in-
strument linearity was checked using commercial standard
reagents (Immuno-Brite Standards Kit, Coulter, Hialeah,
FL) prior to study. The fluorescence compensations were
set prior to every analysis using calibrate beads (caliBRITE,
Becton Dickinson) and FACSComp Software (Becton Dick-
inson). Instrument calibration was additionally checked
using Immunobrite level II standard beads (Coulter). On
the basis of the data thus obtained, the interassay variability
in this study was 6.5% for FL1 channel and 7.6% for FL2
channel.
The percentages of cells were calculated on the basis
of data obtained from two-color immunofluorescence dot
blot. Analyses were carried out using CellQUEST Software
(Becton Dickinson). Quadrant markers were set relative to
negative immunoglobulin isotype controls in a such way that
99% (99.05±0.04) of the cells labeled with the control anti-
bodies were located in the left lower quadrant. The intensity
of antigen expression in the cell membrane was analyzed in a
histogram data display using logarithmic scale. The number
of CD45-positive cells was always >98% (99.79 ± 0.35).
The mean proportion of CD14-positive cells in an analyzed
gate was 0.77% (S.D., 1.11; range 0.05–6.82).
2.3. Chemo- and radiosensitivity in vitro
The cells were washed twice with phosphate-buffered
saline (PBS, pH 7.4) and once with complete medium con-
sisting of RPMI 1640 (20 mM Hepes, ICN Biochemicals,
Costa Mesa, CA), 10% heat-inactivated fetal calf serum
(Gibco BRL, Paisley, Scotland), 2 mM l-glutamine (Gibco
BRL) and antibiotics (Gibco BRL, penicillin 50 U/ml,
streptomycin 50g/ml). Cytotoxic effects were assessed in
4-day cultures, adding five different concentrations of test
compounds to cultures in 96-well microplates. Alternatively,
the cells were initially irradiated with five different doses
of ionizing and UV-irradiation. A total of 200,000 cells per
well were seeded in a volume of 100l (2 × 106 cells/ml).
The test substances were selected according to their use-
fulness in CLL therapy on one hand and on the basis of
their individual mechanisms of action on the other. Ef-
fects were monitored by assessing protein synthesis using
[14C]-leucine incorporation. We have demonstrated that
with various toxic drugs, leucine incorporation is tightly
correlated to the number of living CLL cells in this type of
assay (see [3] and references therein). The ID80 (80% de-
crease in leucine incorporation) values were calculated from
dose-response curves representing duplicate or triplicate
cultures of six different drug concentrations.
3. Results
Expression of CD80 divided the patients into two
mutually exclusive groups as regards sensitivity to the
purine analogs 2′-chlorodeoxyadenosine and fludarabine.
All resistant cases had very low CD80 expression as indi-
cated by the percentage of positive cells or by geometric
mean fluorescence (Fig. 1). A similar trend, although not
exclusive, was observed with chlorambucil, doxorubicin
and prednisolone, but not with the other drugs or two types
of irradiation tested. No statistically significant correlations
were found between expression of any other surface antigen
and drug sensitivity, when analyzed by using Spearman’s
rank order correlation test.
4. Discussion
Purine analogs are promising antileukemic compounds
competing with chlorambucil in first line therapy in CLL.
In fact, the results of a recent clinical trial justified the con-
clusion that fludarabine yields higher response rates and a
longer duration of remission and progression-free survival
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Fig. 1. CD80 expression and ex vivo sensitivity of CLL cells to nine drugs and two types of irradiation. Peripheral blood mononuclear cells from 36
CLL patients were examined. The ex vivo chemo- and radiosensitivities of CLL cells were determined in 4-day cultures by exposing the cells to six
doses of the toxic agents. ID80 values were determined from the dose-response curves. These indicate the doses causing an 80% decrease in cell viability.
Expression of CD80 was determined by using flow cytometry and fluorescent monoclonal antibodies. It was examined by determination of geometric
mean fluorescence (upper panel) and the percentage of positive cells (lower panel). Similar results were obtained by both means.
than chlorambucil, but overall survival is not enhanced [4].
However, among 170 patients treated with fludarabine, 63
(37%) had stable or progressive disease. Hence, novel tools
for individualizing chemotherapy are required. Our current
data demonstrate that the ex vivo cellular response to flu-
darabine can be predicted using CD80 expression as a sur-
rogate marker of chemosensitivity. None of the cases with
detectable expression of this antigen was resistant when
cells were tested in vitro. The same feature was observed
with 2-chlorodeoxyadenosine. High expression of CD80
also excluded the resistance of CLL cells to doxorubicin,
chlorambucil and prednisolone. Interestingly, CD80 status
did not correlate to CD38 expression, which has appeared to
a versatile predictor of clinical outcome in B-CLL cases [5].
Very little is known about the biological role of CD80.
It has been shown that in follicular lymphoma the priming
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of malignant B cells with CD40L induces an increase in
CD80/CD86 expression and a consequent recognition of
these cells by normal T lymphocytes [6]. The data here in-
dicate that the function of CD80 is not specifically related to
purine analog pharmacodynamics. The usefulness of CD80
expression as a predictive marker of purine analog sensitiv-
ity deserves clinical validation. A better understanding of
the biochemical function of CD80 may bring new light to
this topic.
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Abstract
Several investigators have now established that chronic lymphocytic leukemia (CLL) is not a uniform disease entity, since approximately
half of the cases of CLL have undergone immunoglobulin V region (IgV) hypermutation, whereas the other half display unmutated
Ig genes. The median survival time of mutated CLL (M-CLL) cases has been shown to be approximately twice as long as that for
unmutated CLL (UM-CLL), but no clear explanation for this difference is currently available. In this work, we have investigated a cohort
of previously untreated CLL patients, to see whether the ex vivo sensitivities of leukemic cells of 16 UM-CLL patients differ from those
of 8 M-CLL patients, using nine different drugs and two types of irradiation. Our results demonstrated very similar ex vivo sensitivities
and tumor cell heterogeneity of sensitivity of UM-CLL and M-CLL cells when tested against chlorambucil, 2-chloro-2′-deoxyadenosine,
cyclosporin A, cis-platinum(II)diammine-dichloride, doxorubicin hydrochloride, 2-fluoroadenine-9--d-arabinofuranoside, prednisolone
sodium succinate, verapamil, vincristine, -irradiation, and UV-irradiation. This indicates that de novo chemo/radiosensitivity cannot
explain the survival difference observed between UM-CLL and M-CLL.
© 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most
common form of leukemia in Western countries. This dis-
ease is characterized by accumulation of mature-looking but
functionally compromised lymphocytes preferentially in the
bone marrow, blood and lymphoid tissues [1].
During an immunological germinal center response,
the immunoglobulin genes of normal polyclonal B cells
are subjected to a hypermutation mechanism resulting in
non-random single base changes in the immunoglobulin V
region (IgV) genes [2]. It has gradually become obvious that
this may also concern cells that have given rise to B lym-
phoid malignancies [3]. For example, CLL consists of two
clinical entities with either somatically mutated (M-CLL)
or unmutated (UM-CLL) VH (heavy-chain variable-region)
genes [3–5]. The two subtypes of CLL are biologically
very interesting and their recognition is also of immediate
∗ Corresponding author. Tel.: +358-3-247-5290; fax: +358-3-247-4048.
E-mail address: juhani.vilpo@tays.fi (J. Vilpo).
clinical relevance, since the two groups of CLL have been
shown to have different prognoses with significantly shorter
median survival for UM-CLL than M-CLL [6–8].
Apart from clinical staging, there are very few reliable
prognostic markers predicting the outcome of CLL [9]. One
natural clinical prognostic marker could be the sensitivity of
CLL cells to chemotherapy. Tumor cell sensitivity in vivo,
however, depends on drug pharmacokinetics as well as on
the internal sensitivity of tumor cells to the chemotherapeu-
tic agents administered. In this work we have investigated,
by using nine different drugs and two types of irradiation,
whether the sensitivities of UM-CLL versus M-CLL cells
differ from each other ex vivo.
2. Materials and methods
2.1. Patients and samples
Clinical specimens were originally obtained after in-
formed consent from 36 consecutive CLL patients referred
0145-2126/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
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to the CLL out-patient clinic at Tampere University Hos-
pital (Finland). Twelve patients were excluded, as de-
scribed below. Thus, the final number of patients included
in this investigation was 24. Diagnosis and staging were
based on standard clinical, morphological and immunophe-
notyping criteria. All patients had a CD19+/CD23+/
CD5+ immunophenotype (the cohort was reanalyzed in
2000); immunophenotyping was performed by flow cytom-
etry (FACSCalibur, Becton Dickinson Immunocytometry
systems, California) using commercial mouse monoclonal
antibodies and respective immunoglobulin isotype controls
[10]. All cases had a mature CLL, CLL/mix or CLL/PL
morphology [11]. Most patients had chromosomal aber-
rations but none indicating chronic lymphoid leukemias
other than typical CLL [12–15]. Others and ourselves have
previously demonstrated that chemotherapy modifies the
in vitro chemosensitivity of CLL cells [16,17]. Hence, of
the original 36 patients, 9 cases were not included in this
investigation because they had received chemotherapy. Ad-
ditionally, three patients had to be excluded since their
IgVH mutation status could not be determined.
Peripheral blood mononuclear cells were isolated from
heparinized (Noparin, Novo Nordik, Dagsvaerd, Denmark)
blood samples by centrifugation over a Lymphoprep layer
(Nycomed, Oslo, Norway) at a density of 1.077 g/ml. The
cells were washed twice with phosphate-buffered saline
(PBS, pH 7.4) and once with medium consisting of RPMI
1640 (20 mM Hepes, ICN Biochemicals, Costa Mesa, CA),
10% heat-inactivated fetal calf serum (Gibco BRL, Paisley,
Scotland), 2 mM l-glutamine (Gibco BRL) and antibiotics
(penicillin, 50 U/ml, streptomycin, 50g/ml, Gibco BRL).
Cell counting was performed by using Technicon H1, H2
or H3 analyzers (Bayer Diagnostica). Density gradient cen-
trifugation yields—without other purification steps—were
good (range 29–92%; mean 61.7%; S.D. 16.2%, n = 36).
This information is necessary for interpretation of the re-
sults [18]. The proportion of monocytes plus polyclonal T-
and B-lymphocytes was 1–13%, indicating that 87–99%
of the isolated cells represented the leukemic population
(reanalyzed in 2000) [10].
2.2. VH gene analysis in UM-CLL versus M-CLL
VH gene family-specific PCR amplification was per-
formed using six family-specific VH primers and one JH
primer, as previously described [19]. The PCR amplification
and the PCR conditions have been detailed recently [19].
To distinguish monoclonal PCR products from polyclonal
ones, single stranded conformation polymorphism analy-
sis was performed using GenePhor system electrophoresis
(Pharmacia Biotech, Uppsala, Sweden), according to the
manufacturer’s instructions.
Clonal PCR products from rearrangements were se-
quenced directly by using BigDye Terminator Cycle Se-
quencing Reaction Kits (Perkin-Elmer, ABI, Foster City,
CA, USA). All sequence reactions were analyzed using
an automated DNA sequencer (ABI 377, Applied Biosys-
tems, Foster City, CA). The obtained sequences were
aligned to the closest published germline genes using the
IgBLAST (National Center for Biotechnology Information,
USA), the V-BASE (MRC Centre for Protein Engineering,
Cambridge, UK) and the international ImMunoGeneT-
ics (http://imgt.cines.fr:8104; Initiator and coordinator:
Marie-Paule Lefranc, Montpellier, France) databases. VH
gene sequences deviating more than 2% from the corre-
sponding germline gene were defined as mutated, whereas
sequences displaying less than 2% mutations were consid-
ered unmutated. For D gene determination, a requirement
of a minimum of seven matching nucleotides was used.
2.3. Chemo- and radiosensitivity in vitro
2.3.1. Drugs and irradiation
The following drugs and types of irradiation were used.
Chlorambucil (Sigma, St. Louis, MO); 2-chloro-2′-deoxy-
adenosine (Sigma); cyclosporin (cyclosporin A, Sandoz
Pharmaceutical Co., Basle, Switzerland); cis-platinum(II)-
diammine-dichloride (cisplatin, Sigma); doxorubicin hy-
drochloride (adriamycin 2 mg/ml, Pharmacia, Uppsala,
Sweden); 2-fluoroadenine-9--d-arabinofuranoside (fluda-
rabine, Sigma); prednisolone sodium succinate; di-Adeson-
F (prednisolone, N.V. Organon, Oss, The Netherlands);
verapamil (verpamil 2.5 mg/ml, Orion Ltd., Espoo, Fin-
land); -irradiation: 0.007 Gy/s (137Cs source; Molsgaard
Medical, Denmark); UV-irradiation: 1 J/(m2 s) (UV Unit;
Gelman Sciences, Ann Arbor, MI).
2.3.2. Cytotoxicity assay
The methodology has been described in more detail in
the original papers [16,20–25]. In short, the cytotoxic ef-
fects of the nine drugs and two types of irradiation against
peripheral blood leukemic cells were assessed using 4-day
cultures, by adding five different concentrations of test drugs
to cultures in 96-well microplates. Alternatively, the cells
were initially irradiated with five different doses of ionizing
and UV-irradiation. A total of 200,000 cells per well were
seeded in a volume of 100l (2 × 106 cells/ml). The test
substances were selected according to their usefulness in
CLL therapy on one hand and on the basis of their individual
mechanisms of action on the other. Effects were monitored
by assessing protein synthesis using [14C]-leucine incor-
poration. [U-14C]-leucine (specific activity 1.3 mCi/mmol,
0.5Ci/ml) was added for the final 24 h of culture. After in-
cubation, the proteins were precipitated with 0.2 M perchlo-
ric acid and collected on glass fiber filters using a multiple
cell harvester (LKB Wallac 1295-001, Turku, Finland). The
radioactivity incorporated was measured by a liquid scin-
tillation counter (Wallac 1410). Values of ID20 and ID80
were calculated from dose–response curves using duplicate
or triplicate assays with five drug/irradiation doses. ID20 and
ID80 are equivalent to a concentration of a drug or a dose
of irradiation which decreases 14C-leucine incorporation by
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20 and 80%, respectively. We have previously shown in a
number of experiments that there is a good correlation be-
tween 14C-leucine incorporation and the number of living
cells in a culture [16,20–25].
2.4. Statistical treatment
The Mann–Whitney U-test was used for group (median)
comparisons: STATISTICA for Windows (Version Win
5.1D, 1996 StatSoft Inc., Tulsa, OK).
3. Results
3.1. VH gene analysis in UM-CLL versus M-CLL
Detailed analysis of gene usage (VH, D and J) and VH
mutation status will be published elsewhere (Vilpo et al.,
submitted for publication). Eight cases (33%) displayed mu-
tated IgVH genes, whereas 16 (67%) cases were unmutated.
3.2. Sensitivities of UM-CLL versus M-CLL cells
The results of cytotoxicity testing of nine drugs and two
kinds of irradiation against the peripheral blood leukemic
cells of 8 M-CLL and 16 UM-CLL cases are illustrated in
Fig. 1. The ID80 values, i.e. doses causing 80% inhibition
in cell viability, as measured by 14C-leucine incorporation,
were surprisingly similarly distributed in both types of CLL.
The large scatter of individual values demonstrates the great
Fig. 1. Sensitivity in vitro of peripheral blood leukemia cells of 16
UM-CLL patients and 8 M-CLL patients to nine drugs and two types
of irradiation. The ID80 values (ID50 for prednisolone, since ID80 was
not achieved in all cases) are expressed in mol/l, with the exception of
-irradiation in Gy, and UV-irradiation in J/m2. Medians and total ranges
are illustrated. Open symbols: UM-CLL; closed symbols: M-CLL.
individual variation of CLL cell sensitivity among different
patients of both CLL types. Statistical analysis did not re-
veal any significant differences between these two types of
disease (P > 0.05). The only exception was prednisolone,
which had to be evaluated at the ID50 level, since ID80 was
not achieved in all cases, even when a high dose of the drug
was tested. UM-CLL cases were, on average, slightly more
sensitive than M-CLL cases (P = 0.041).
In addition to evaluating variation between patients by
using the ID80 values, we also evaluated whether VH muta-
tion status affects the variation of drug/irradiation sensitiv-
ity in individual patients, i.e. we evaluated the distribution
of heterogeneity of intra-individual sensitivity in cases of
M-CLL versus UM-CLL. To this end, we also determined
the ID20 values and adopted the ratio of ID80 per ID20 as a
measure of that parameter. The results illustrated in Table 1
clearly demonstrate that there were no significant differences
in intra-individual heterogeneity of sensitivity to any of the
toxic agents in these two groups of CLL.
4. Discussion
The present work was performed in order to establish
whether different drug or irradiation sensitivities could con-
tribute to the longer survival of patients with M-CLL versus
UM-CLL, but this could not be confirmed.
Many prognostic factors for CLL have been proposed
(for a review, see [9]), but so far few investigations con-
cerning their occurrence in UM-CLL versus M-CLL have
yet been published. Preliminary information suggests, for
example, that 13q deletion as a single chromosomal aber-
ration (a marker of good prognosis), is more frequent in
M-CLL, whereas 11q deletion (a marker of bad prog-
nosis) is preferentially associated with UM-CLL [26]. It
remains to be shown, however, whether this or other kinds
of prognostic indicator may explain the survival difference
between patients with UM-CLL versus M-CLL. Intensive
gene expression studies have revealed <30 gene expression
differences when the expression of about 12,000 genes in
UM-CLL versus M-CLL was compared [27].
The other conceivable explanation for the survival differ-
ence of UM-CLL versus M-CLL patients could be different
chemo- and radiosensitivity in these two forms of CLL.
The most reliable way to investigate this topic would be a
clinical study. At the time being this is not possible, since
(i) there are no such clinical chemosensitivity data avail-
able concerning IgVH-characterized patients, (ii) tumor cell
concentrations of various drugs in vivo are not known,
and (iii) a clinical trial comparing UM-CLL and M-CLL
in a randomized study would be difficult to organize. The
present work was performed in order to provide prelimi-
nary information about chemo- and radiosensitivity in the
two forms of CLL. The cellular sensitivities ex vivo could
be investigated without the interfering factors mentioned
above. Overall, the two types of CLL demonstrated similar
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Table 1
Heterogeneity of sensitivity of UM-CLL and M-CLL cells to nine drugs and two types of irradiationa
Drugs and irradiation types UM-CLL M-CLL Mann–Whitney
U (P-value)
Mean S.D. Mean S.D.
Chlorambucil 14.8 12.7 15.4 7.7 0.4260
Chlorodeoxyadenosine 40.7 44.9 24.7 23.5 0.3425
Fludarabine 19.4 25.7 9.3 3.3 0.5815
Cisplatinum 9.7 5.1 7.2 3.2 0.0662
Doxorubicin 19.9 20.7 27.9 40.5 0.7383
Prednisolone 72.15 244.27 93.52 123.15 0.0758
Vincristine 47.4 49.1 74.3 141.0 0.8065
-Irradiation 31.8 31.9 30.4 19.2 0.7595
UV-irradiation 6.1 2.4 8.4 3.7 0.1417
Cyclosporin A 4.5 3.5 2.3 1.5 0.0662
Verapamil 16.4 17.7 15.1 12.7 0.3913
a The figures represent ID80/ID20 ratios with the exception of prednisolone, for which the ratio ID50/ID20 was determined.
cellular sensitivity to nine drugs and two forms of irradia-
tion. M-CLL had a tendency to be slightly more sensitive to
2-chloro-2′-deoxyadenosine and vincristine than UM-CLL,
whereas the opposite was shown for UV-irradiation, but
no significant difference was shown between the subsets.
The only statistically significant difference concerned pred-
nisolone, for which UM-CLL cases were more sensitive
than M-CLL (P = 0.04). Furthermore, the intra-individual
or tumor cell heterogeneity of chemo/radiosensitivity in
both groups was very similar. This indicates that de novo
chemo/radiosensitivity cannot explain the survival dif-
ference observed between patient with UM-CLL versus
M-CLL. Our results, on the other hand, do not exclude
the possibility that UM-CLL cells might achieve resistance
during clinical chemotherapy faster than do M-CLL cells.
However, the observed tendencies of difference in cellular
resistance for some of the single drugs between the mutated
and unmutated CLL cases warrant further investigation in
a larger patient material to make clear if the findings are
significant.
In conclusion, the current pilot study demonstrated very
similar ex vivo sensitivities and tumor cell heterogeneity of
sensitivity of UM-CLL and M-CLL cells when tested against
chlorambucil, 2-chloro-2′-deoxyadenosine, cyclosporin A,
cis-platinum(II)diammine-dichloride, doxorubicin hydroch-
loride, 2-fluoroadenine-9--d-arabinofuranoside, predniso-
lone sodium succinate, verapamil, vincristine, -irradiation,
and UV-irradiation.
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